

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number
WO 03/089605 A2

- (51) International Patent Classification⁷: C12N (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/US03/12045
- (22) International Filing Date: 18 April 2003 (18.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/374,627 22 April 2002 (22.04.2002) US
- (71) Applicant (*for all designated States except US*): GENENCOR INTERNATIONAL, INC. [US/US]; 925 Page Mill Road, Palo Alto, CA 94304 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): SOUCAILLE, Philippe [FR/FR]; Chant du Coucou, F-31450 Deyme (FR).
- (74) Agent: ITO, Richard, T.; GENENCOR INTERNATIONAL, INC., 925 Page Mill Road, Palo Alto, CA 94304 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD OF CREATING A LIBRARY OF BACTERIAL CLONES WITH VARYING LEVELS OF GENE EXPRESSION



(57) Abstract: The present invention relates to a method of creating DNA libraries that include an artificial promoter library and/or a modified ribosome binding site library and transforming bacterial host cells with the library to obtain a population of bacterial clones having a range of expression levels for a chromosomal gene of interest.

**METHOD OF CREATING A LIBRARY
OF BACTERIAL CLONES
WITH VARYING LEVELS OF GENE EXPRESSION**

FIELD OF INVENTION

The present invention relates to the genetic modification of bacterial cells. Particularly to a method of creating DNA libraries that comprise a library of artificial promoters and/or a library of modified regulatory regions, and the use of the libraries to replace precursor promoters and regulatory regions in bacterial host cells resulting in a library of bacterial clones having a range of expression levels of a gene of interest.

BACKGROUND OF THE INVENTION

For many years microorganisms have been exploited in industrial applications for the production of valuable commercial products, such as industrial enzymes, hormones and antibodies. Despite the fact that recombinant DNA technology has been used in an attempt to increase the productivity of these microorganisms, the use of metabolic genetic engineering to improve strain performance, particularly in industrial fermentations has been disappointing.

A common strategy used to increase microbial strain performance is to alter gene expression, and a number of means have been used to achieve this end. One approach includes the cloning of a heterologous or a homologous gene in a multi-copy plasmid in a selected host strain. Another approach concerns altering chromosomal gene expression. This has been accomplished by various methods some of which include: (1) site-specific mutations, deletions or insertions at a predetermined region of a chromosome; (2) reliance on transposons to insert DNA randomly into chromosomes and (3) altering of native regulatory regions of a gene at its chromosomal location. The alteration of regulatory regions can be accomplished for example, by changing promoter strength or by using regulatable promoters which are influenced by inducer concentration. Reference is made to Jensen and Hammer, (1998) *Biotechnology and Bioengineering* 58:193 - 195; Jensen and Hammer (1998) *Appl. Environ. Microbio.* 64:82 - 85; and Khlebnikov et al. (2001) *Microbiol.* 147:3241. Other techniques used to replace regulatory regions of chromosomal gene have been disclosed in Abdel-Hamid et al. (2001) *Microbiol.* 147:1483 - 1498 and Repoila and Gottesman (2001) *J. Bacteriol.* 183:4012 - 4023.

With respect to optimizing metabolic pathway engineering in a selected host, the above-mentioned approaches have had limited success and each approach has certain disadvantages. Research has shown the expression level of a genetically modified gene on a plasmid is not necessarily correlated with the level of expression of the same modified gene located in the chromosome (See Khlebnikov et al. (2001) *Microbiol.* 147:3241 and McCracken and Timms (1999) *J. Bacteriol.* 18:6569).

- 2 -

Moreover, the effect of increasing expression of one gene in a metabolic pathway may only have a marginal effect on the flux through that metabolic pathway. This may be true even if the gene being manipulated codes for an enzyme in a rate-limiting step because control of a metabolic pathway may be distributed over a number of enzymes. Therefore, while a gene has been
5 engineered to achieve a high level of expression, for example a 10 to 100 fold increase in expression, the overall performance of the engineered microorganism in a bioreactor may decrease. The decrease could be due to the balance of other factors involved in the metabolic pathway or the depletion of other substances necessary for optimum cell growth.

The above problem is addressed in part by Jensen and Hammer (WO 98/07846). The
10 disclosure of WO98/07846 describes the construction of a set of constitutive promoters that provide different levels of gene expression. Specifically, artificial promoter libraries are constructed comprising variants of a regulatory region that includes a -35 consensus box, a -10 consensus box and a spacer (linker) region that lies between these consensus regions. However, one of the
15 drawbacks of the method described in WO 98/07846 is the extensive screening (in terms of time and numbers of steps), which would be required to create a library of clones with different levels of gene expression. It is also disclosed in the reference that the modulation of promoter strength, by a few base-pair changes in the consensus sequences or by changes in the linker sequence, would result in a large impact in promoter strength, and therefore, it would not be feasible to achieve small steps on promoter strength modulation.

20 Therefore, a need still exists in the area of metabolic pathway engineering to develop a quick and efficient means of determining the optimum expression of a gene of interest in a metabolic pathway which in turn results in an optimization of strain performance for a desired product. The present method satisfies this need by providing a method to characterize small changes in gene expression level and hence allowing for the selection of a cell providing an optimum level of
25 expression.

SUMMARY OF THE INVENTION

In one aspect the invention relates to a method of creating a library of artificial promoters comprising a) obtaining an insertion DNA cassette, which comprises, a first recombinase site, a
30 second recombinase site and a selective marker gene located between the first and the second recombinase sites; b) obtaining a first oligonucleotide which comprises, i) a first nucleic acid fragment homologous to an upstream region of a chromosomal gene of interest, and ii) a second nucleic acid fragment homologous to a 5' end of the insertion DNA cassette; c) obtaining a second oligonucleotide which comprises, i) a third nucleic acid fragment homologous to a 3' end of said
35 insertion DNA cassette, ii) a precursor promoter comprising a -35 consensus region (-35 to -30), a linker sequence and a -10 consensus region (-12 to -7), wherein the linker sequence comprises between 14 - 20 nucleotides and is flanked by the -35 region and the -10 region, wherein said precursor promoter has been modified to include at least one modified nucleotide position of the precursor promoter and wherein the -35 region and the -10 region each include between 4 to 6

- 3 -

conserved nucleotides of the promoter, and iii) a fourth nucleic acid fragment homologous to a downstream region of the transcription start site of the promoter; and d) mixing the first oligonucleotide and the second oligonucleotide in an amplification reaction with the insertion DNA cassette to obtain a library of double stranded amplified products comprising artificial promoters. In one embodiment, the method further comprises purifying the amplified products. In another embodiment, the amplification step is by PCR. In another embodiment, the precursor promoter is selected from the group consisting of P_{trc} (SEQ ID NO. 2); P_{D/E20} ((SEQ ID NO. 4); P_{H207} (SEQ ID NO. 3); P_{N25} (SEQ ID NO. 5); P_{G25} (SEQ ID NO.6); P_{J5} (SEQ ID NO.7); P_{A1} (SEQ ID NO. 8); P_{A2} (SEQ ID NO. 9); P_{A3} (SEQ ID NO. 10); P_{lac} (SEQ ID NO. 1); P_{lacUV5} (SEQ ID NO. 12); P_{CON} (SEQ ID NO.4); P_{GI} (SEQ ID NO. 15) and P_{b16} (SEQ ID NO. 14). In a further embodiment the artificial promoter library includes the promoters designated by SEQ ID NO. 15, SEQ ID NO. 16 and SEQ ID NO. 17. In a further embodiment the invention includes the artificial promoter library produced according to the above method.

In a second aspect, the invention relates to a method of creating a library of ribosome binding sites (RBS) comprising a) obtaining an insertion DNA cassette, which comprises, a first recombinase site, a second recombinase site and a selective marker gene located between the first and the second recombinase sites; b) obtaining a first oligonucleotide which comprises, i) a first nucleic acid fragment homologous to an upstream region of a chromosomal gene of interest, and ii) a second nucleic acid fragment homologous to a 5' end of the insertion DNA cassette; c) obtaining a second oligonucleotide which comprises, i) a third nucleic acid fragment homologous to a 3' end of said insertion DNA cassette, ii) a precursor promoter comprising a -35 consensus region (-35 to -30), a linker sequence and a -10 consensus region (-12 to -7), wherein the linker sequence comprises between 14 - 20 nucleotides and is flanked by the -35 region and the -10 region, wherein said precursor promoter has been modified to include at least one modified nucleotide position of the precursor promoter and wherein the -35 region and the -10 region each include between 4 to 6 conserved nucleotides of the promoter, and iii) a fourth nucleic acid fragment homologous to a downstream region of the transcription start site of the promoter; and d) mixing the first oligonucleotide and the second oligonucleotide in an amplification reaction with the insertion DNA cassette to obtain a library of double stranded amplified products comprising artificial promoters and e) obtaining a third oligonucleotide which comprises, i) a fifth nucleic acid fragment homologous to the 5' end of said chromosomal gene of interest, ii) a modified ribosome binding site of the gene of interest, said ribosome binding site including at least one modified nucleotide, and iii) a sixth nucleic acid fragment homologous to a downstream region of the -10 region of the second oligonucleotide; and e) mixing the PCR products of step d) with the third oligonucleotide of step e) and the first oligonucleotide of step b) in a PCR reaction to obtain PCR products comprising artificial promoters with modified ribosome binding sites. In an embodiment the ribosome binding site is selected from the group consisting of AGGAAA, (SEQ ID NO. 30), AGAAAA (SEQ ID NO. 31), AGAAGA (SEQ ID NO. 32), AGGAGA (SEQ ID NO. 33), AAGAAGGAAA (SEQ ID NO. 34), AAGGAAAA (SEQ ID NO. 35), AAGGAAAG (SEQ ID NO. 36), AAGGAAAU (SEQ ID NO. 37), AAGGAAAAA (SEQ ID NO.

- 4 -

38), AAGGAAAAG (SEQ ID NO. 39), AAGGAAA AU (SEQ ID NO. 40), AAGGAAAAA (SEQ ID NO. 41), AAGGAAAAAG (SEQ ID NO. 42), AAGGAAAA AU (SEQ ID NO. 43), AAGGAAAAA (SEQ ID NO. 44), AAGGAAAAAG (SEQ ID NO. 45), AAGGAAAA AU (SEQ ID NO. 46), AAGGAAAAA (SEQ ID NO. 47), AAGGAAAAAG (SEQ ID NO. 48), AAGGAAAA AU (SEQ ID NO. 49), AAGGAAAAA (SEQ ID NO. 50), AAGGAAAAAG (SEQ ID NO. 51), AAGGAAAA AU (SEQ ID NO. 52), AAGGAAAAA (SEQ ID NO. 53), AAGGAAAAAG (SEQ ID NO. 54), AAGGAGGAAA (SEQ ID NO. 55), and AAGGAAAA AU (SEQ ID NO. 56). In a further embodiment the invention includes the artificial promoter library produced according to the above method.

10 In a third aspect, the invention relates to an artificial promoter library comprising a mixture of double stranded polynucleotides which include in sequential order: a) a nucleic acid fragment homologous to an upstream region of a chromosomal gene of interest, b) a first recombinase site, c) a nucleic acid sequence encoding an antimicrobial resistance gene, d) a second recombinase site, e) two consensus regions of a promoter and a linker sequence, wherein the first consensus
15 region comprises a -35 region, the second consensus region comprises a -10 region and the linker sequence comprises at least 14 - 20 nucleotides and is flanked by the first consensus region and wherein the second consensus region and the -35 region and the -10 region each include between 4 - 6 conserved nucleotides of corresponding consensus regions of the promoter, and f) a nucleic acid fragment homologous to the downstream region of the +1 transcription start site of the promoter. In
20 one embodiment the promoter library of the double stranded polynucleotides will also include a modified start codon, wherein the modified start codon sequence is located between the -10 region and the nucleic acid sequence homologous to the downstream region of the +1 transcription start site. In another embodiment the promoter library of double stranded polynucleotides further include a stabilizing mRNA nucleic acid sequence, wherein the stabilizing mRNA sequence is located
25 between the -10 region and the nucleic acid sequence homologous to the downstream region of the +1 transcription start site.

In a fourth aspect, the invention relates to a method of modifying a promoter in selected host cells comprising obtaining a library of PCR products comprising artificial promoters, RBS, start codons or stabilizing mRNA sequences or combinations thereof according to the invention; b)
30 transforming bacterial host cells with the PCR library, wherein the PCR products comprising the artificial promoters are integrated into the bacterial host cells by homologous recombination; c) growing the transformed bacteria cells; d) selecting the transformed bacterial cells comprising the artificial promoters. In certain embodiments the bacterial host cell is selected from the group consisting of *E. coli*, *Pantoea sp.* and *Bacillus sp.*

35 In a fifth aspect, the invention relates to a method of creating a library of bacterial cells having a range of expression levels of a chromosomal gene of interest comprising, a) obtaining a library of PCR products comprising artificial promoters according to the invention; b) transforming bacterial host cells with the PCR products, wherein the PCR products comprising the artificial promoters are integrated into bacterial host cells by homologous recombination to produce

- 5 -

transformed bacterial cells; c) growing the transformed bacteria cells; and d) obtaining a library of transformed bacterial cells wherein the library exhibits a range of expression levels of a chromosomal gene of interest. In one embodiment the method further comprises selecting transformed bacterial cells from the library. In a second embodiment the selected transformed cells will have a low level of expression of the gene of interest, and in another embodiment the selected transformed bacterial cells have a high level of expression of the gene of interest.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates a schematic representation of a method of creating an artificial promoter library and the double stranded PCR products obtained according to the method of the invention. Two oligonucleotides which are represented by numbers (1) and (2) and an insertion DNA cassette on a plasmid (3) are mixed together in a PCR reaction to form a mixture of double stranded PCR products. Oligonucleotide (1) includes nucleic acid sequences homologous to an upstream region of a chromosomal gene of interest (H1) and a primer site (PS1). The PS1 is homologous to the first end (5') of an insertion DNA cassette (3). Oligonucleotide (2) is degenerated and includes a primer site (PS2) and artificial promoter sequences (H2). The PS2 is homologous to the second end (3') of the insertion DNA cassette (3). The artificial promoter sequences (H2) comprise different modified -35 consensus regions, different modified linker regions, and different modified -10 consensus regions or combinations thereof. The insertion DNA construct (3) includes a selective marker, which is preferably an antibiotic resistant gene, flanked by two recombinase sites (FRT).

Figure 2 is a schematic representation of the method of creating a DNA library comprising artificial promoters, modified ribosome binding sites, mRNA stabilizing sequences, and/or modified start codons according to the invention. In this figure, the mixture of double stranded PCR products of Figure 1 are mixed in a further PCR reaction with the oligonucleotide (1) and a third oligonucleotide (4) comprising a nucleic acid fragment homologous to the 5' end of the gene of interest (which is the same gene of interest in Figure 1) a start codon, which may be a modified start codon; a modified ribosome binding site of the precursor promoter; a stabilizing mRNA segment and a nucleic acid fragment homologous to a downstream region of the start codon of the gene of interest to obtain a new mixture of double stranded PCR products. X indicates that the start codon may be modified.

Figure 3 is a schematic representation of the replacement of a chromosomal regulatory sequence with the PCR products according to the invention.

Figure 4 illustrates the sequences of various well-characterized promoters and includes approximately 50 base pair (bp) upstream of the transcription start site (+1), including the -35 consensus boxes, the linker sequences and the -10 consensus boxes. The promoters are aligned with respect to the first T of the -35 consensus box and the last T of the -10 consensus box. The conserved regions are indicated in bold. P_{D/E20} is represented by SEQ ID NO. 3; P_{H207} is represented by SEQ ID NO. 4; P_{N25} is represented by SEQ ID NO. 5; P_{G25} is represented by SEQ ID NO. 6; P_{J5} is represented by SEQ ID NO. 7; P_{A1} is represented by SEQ ID NO. 8; P_{A2} is represented by SEQ ID

- 6 -

NO. 9; P_{A3} is represented by SEQ ID NO. 10; P_L is represented by SEQ ID NO. 11; P_{lac} is represented by SEQ ID NO. 1; P_{lacUV5} is represented by SEQ ID NO. 12; P_{lacI} is represented by SEQ ID NO. 2; P_{con} is represented by SEQ ID NO. 13; and P_{bla} is represented by SEQ ID NO. 14.

Figure 5 compares the chromosomal organization of the lactose operon of the wild-type strain (A) and chromosomal organization of a host strain transformed with a promoter (B) according to the invention.

Figure 6 illustrates a library of promoters comprising three artificial promoters used to replace the lactose operon promoter $Plac$ (SEQ ID NO. 18) and the $lacI$ regulator. The library of promoters comprises three artificial glucose isomerase promoters: 1.6 GI $lacZ$ (SEQ ID NO. 19) which includes the 1.6GI promoter (SEQ ID NO. 15); 1.5 GI $lacZ$ (SEQ ID NO. 20) which includes the 1.5GI promoter (SEQ ID NO. 16); and 1.2 GI $lacZ$ (SEQ ID NO. 21) which includes the 1.2GI promoter (SEQ ID NO. 17).

Figure 7 illustrates the expression of the $lacZ$ gene measured as specific activity of β -galactosidase in a library of *E. coli* cells transformed with the library comprising 1.6 GI $lacZ$ (SEQ ID NO. 19), 1.5 GI $lacZ$ (SEQ ID NO. 20) and 1.2 GI $lacZ$ (SEQ ID NO. 21).

Figure 8 illustrates the expression of the $lacZ$ gene with the 1.6GI promoter (SEQ ID NO. 19), wherein the ribosome binding site has been altered. Transformants are designated

A = CAAGGAGGAA ACAGCTATG (SEQ ID NO.22),

B = CAAGAAGGAA ACAGCTATG (SEQ ID NO. 23),

20 C = CACACAGGAA ACAGCTATG (SEQ ID NO. 24) ,

D = CTCACAGGAG ACAGCTATG (SEQ ID NO. 25),

E = CTCACAGGAA ACAGCTATG (SEQ ID NO. 26),

F = CACACAGAAA ACAGCTATG (SEQ ID NO. 27),

G = CTCACAGAGA ACAGCTATG (SEQ ID NO. 28), and

25 H = CTCACAGAAA ACAGCTATG (SEQ ID NO. 29).

Figure 9 illustrates the expression of the $lacZ$ gene with the 1.6GI promoter (SEQ ID NO. 19), wherein the ribosome binding site (AGGAAA) has been altered and a stabilizing mRNA sequence has been inserted.

30 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method of creating a library of bacterial clones from amplified DNA libraries, particularly PCR generated DNA libraries, wherein the bacterial clones express a chromosomal gene of interest at different levels. The generated DNA libraries include any one of the following libraries, artificial promoters, ribosome binding sites (RBS), start codons and mRNA stabilizing sequences. An advantage of the method disclosed herein is that only one *in vivo* step is required to create the library of bacterial clones.

One aspect of the present invention relates to the discovery, that gene expression level is changed by altering one or two nucleotides in the -35 consensus region (-35 box), the -10 consensus region (-10 box), the linker region, the RBS, and/or the start codon and further that the

- 7 -

alteration allows a quick identification of a range of gene expression that would produce a significant phenotypic change. A second aspect, the invention relates to the use of precursor promoter sequences, RBSs, start codons and/or mRNA stabilizing sequences which are contained within one or two degenerated oligonucleotides so that the DNA library may be generated by one or two
5 amplification steps.

Definitions

Within this application, unless otherwise stated, illustration of the techniques used may be found in any of several well-known references such as: Sambrook, J., et al., MOLECULAR CLONING: A
10 LABORATORY MANUAL, Cold Spring Harbor Laboratory Press (1989); Goeddel, D., ed., GENE
EXPRESSION TECHNOLOGY, METHODS IN ENZYMOLOGY, 185, Academic Press, San Diego, Calif.
(1991); "GUIDE TO PROTEIN PURIFICATION" in Deutscher, M. P., ed., Methods in Enzymology,
Academic Press, San Diego, Calif. (1989); and, Innis, et. al., PCR PROTOCOLS: A GUIDE TO METHODS
AND APPLICATIONS, Academic Press, San Diego, Calif. (1990). Unless defined otherwise, all technical
15 and scientific terms used herein have the same meaning as commonly understood by one or
ordinary skill in the art to which this invention pertains. Both Singleton et al., DICTIONARY OF
MICROBIOLOGY AND MOLECULAR BIOLOGY, 2D. Ed., John Wiley and Sons, New York (1994) and Hale
and Martin, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, New York (1991)
provide one of skill in the art with general dictionaries of many of the terms used in this invention.

20 Although any methods and materials similar or equivalent to those described herein can be
used in the practice or testing of the present invention, the preferred methods and materials are
described. Numeric ranges are inclusive of the numbers defining the range.

Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino
acid sequences are written left to right in amino to carboxy orientation, respectively. The headings
25 provided herein are not limitations of the various aspects or embodiments of the invention which can
be had by reference to the specification as a whole. Accordingly, the terms defined immediately
below are more fully defined by reference to the specification as a whole. The references, issued
patents and pending patent applications cited herein are incorporated by reference into this
application.

30 For the purpose of this invention "a DNA library" includes any one or a combination of the
following, artificial promoter libraries, modified ribosome binding site (RBS) libraries, modified start
codon libraries, and stabilizing mRNA libraries. While a library may include 10^3 or more members, in
preferred embodiments a library will include at least 2, at least 3, at least 4, at least 6, at least 8, at
least 16 or at least 64 members. A DNA library also refers to double stranded DNA molecules.

35 For the purposes of this application, a "promoter" or "promoter region" is a nucleic acid
sequence that is recognized and bound by a DNA dependent RNA polymerase during initiation of
transcription. The promoter, together with other transcriptional and translational regulatory nucleic
acid sequences (also termed "control sequences") is necessary to express a given gene or group of
genes (an operon). In general, the transcriptional and translational regulatory sequences include,

- 8 -

but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. The "transcription start site" means the first nucleotide to be transcribed and is designated +1.

Nucleotides downstream of the start site are numbered +2, +3, +4 etc., and nucleotides in the
5 opposite (upstream) direction are numbered -1, -2, -3 etc. A promoter may be a regulatable promoter, such as P_{trc}, which is induced by IPTG or a constitutive promoter.

In the context of the present invention, a promoter includes two consensus regions. A consensus region is a distinct group of conserved short sequences recognized by RNA polymerases differing in their sigma factors. One consensus region is centered about 10 base pairs (bp) upstream
10 from the start site of transcription initiation and is referred to as the -10 consensus region (-10 box or *Pribnow* box). The other consensus region is centered about 35 bp upstream of the transcriptional start site and is referred to as the -35 consensus region (-35 box). A linker sequence extends between each consensus region and is comprised of about 14 to 20 bp.

A precursor promoter according to the invention may be a native (endogenous) promoter or
15 an exogenous promoter. Further a precursor promoter may be a genetically engineered promoter that is either heterologous or homologous to a gene of interest. Generally precursor promoters will be in the range of 250 to 25 base pairs (bp); 150 to 25 bp; 100 to 25 bp; 75 to 25 bp and preferably 50 to 30 bp from the transcription start site (+1).

An "artificial promoter" according to the invention is a precursor promoter that has been
20 modified by altering a nucleotide in at least one position corresponding to a position in the -35 box, the -10 box and/or the linker sequence. In a preferred embodiment, an artificial promoter will comprise 30 to 50 bp upstream of the transcription start site (+1) and will be derived from a precursor promoter having 50 to 30 bp.

A "library of promoters" refers to a population of promoters which includes artificial
25 promoters, having at least two members. In one embodiment a library will be derived from the same precursor promoter.

A "ribosome binding site" (RBS) is a short nucleotide sequence usually comprising about 4 –
16 base pairs and functions by positioning the RBS on the mRNA molecule for translation of an encoded protein. A "modified ribosome binding" site is a ribosome binding site wherein one or more
30 base pairs have been altered. A preferred modified RBS is derived from the same regulatory region as a precursor promoter when both the precursor promoter and RBS are modified and used in the same library. A library of modified ribosome binding sites includes at least two modified ribosome binding sites derived from the same precursor.

A "stabilizing mRNA" is a nucleic acid sequence insert used to influence gene expression.
35 These inserts are generally located between the transcription and translational start sites of a gene or nucleic acid sequence.

A "library of bacterial clones" refers to a population of bacterial cells grown under essentially the same growth conditions and which are identical in most of their genome but include a DNA

library as defined herein which may comprise for example a library of artificial promoters. A library of bacterial clones will have different levels of expression of the same gene of interest.

As used herein, the term "nucleic acid" includes RNA, DNA and cDNA molecules. It will be understood that, as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding a given protein may be produced. The term nucleic acid is used interchangeably with the term "polynucleotide". An "oligonucleotide" is a short chain nucleic acid molecule. A primer is an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced, (*i.e.*, in the presence of nucleotides and an inducing agent such as DNA polymerase and at a suitable temperature and pH). The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method.

As used herein, the term "gene" means the segment of DNA involved in producing a polypeptide chain, that may or may not include regions preceding and following the coding region (*e.g.* 5' untranslated (5' UTR) or "leader" sequences and 3' UTR or "trailer" sequences), as well as intervening sequences (introns) between individual coding segments (exons).

As used herein the term "polypeptide" refers to a compound made up of amino acid residues linked by peptide bonds. The terms protein, peptide and polypeptide are used interchangeably herein.

The term "modification" includes a deletion, insertion, substitution or interruption of at least one nucleotide or amino acid in a sequence.

As used herein, a "deletion" is defined as a change in either a nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

As used herein, an "insertion" or "addition" is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to a parent sequence.

As used herein, a "substitution" results from the replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively.

In one embodiment a modified DNA sequence is generated with site saturation mutagenesis in at least one nucleotide. In another embodiment, site saturation mutagenesis is performed for two or more nucleotides. In a further embodiment, a modified or mutant DNA sequence has more than 40%, more than 45%, more than 50%, more than 55%, more than 60%, more than 65%, more than 70%, more than 75%, more than 80%, more than 85%, more than 90%, more than 95%, more than 96%, more than 97%, or more than 98% homology with a wild-type sequence from which it was

- 10 -

modified from. In alternative embodiments, mutant DNA is generated *in vivo* using any known mutagenic procedure such as, for example, radiation, nitrosoguanidine and the like.

A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Linking of nucleic acid sequences may be accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers may be used in accordance with conventional practice.

As used herein a "DNA construct" refers to a nucleic acid sequence or fragment that is used to introduce sequences into a host cell or organism. The DNA may be generated *in vitro* by PCR or any other suitable techniques. In some embodiments a DNA construct according to the invention comprises homologous upstream (5') and/or homologous downstream (3') sequences to a precursor promoter, a gene of interest or to another DNA segment. In yet another embodiment a DNA construct may be inserted into a vector. The DNA constructs may include homologous or heterologous sequences to a host cell gene and further may include a combination of heterologous sequences and homologous sequences. In some embodiments, a DNA construct will include a selective marker gene. In other embodiments, a DNA construct will include an artificial promoter and in other embodiments a DNA construct will include a modified RBS sequence, a modified translational start codon and stabilizing mRNA sequences. These DNA constructs are sometimes referred to herein collectively or individually as "regulatory DNA constructs".

As used herein, the term "vector" refers to a nucleic acid construct designed for transfer between different host cells. A vector may be a plasmid, a bacteriophage, a cloning vector, a shuttle vector or an expression vector. An "expression vector" refers to a vector that has the ability to incorporate and express heterologous DNA fragments in a foreign cell. Many prokaryotic and eukaryotic expression vectors are commercially available. Selection of appropriate expression vectors is within the knowledge of those having skill in the art. Vectors used in the process of the may be any vector suitable for isolation and characterization of a promoter.

As used herein, a "flanking sequence" refers to any sequence that is either upstream or downstream of the sequence being discussed (e.g., for genes A B C, gene B is flanked by the A and C gene sequences). In some embodiments, a flanking sequence is present on only a single side (either 3' or 5') of a DNA fragment, but in preferred embodiments, it is on each side of the sequence being flanked.

As used herein the terms, "heterologous nucleic acid sequence" or heterologous DNA construct" refers to a portion of a genetic sequence that is not native to the cell in which it is expressed. "Heterologous," with respect to a control sequence refers to a control sequence (*i.e.*, promoter) that does not function in nature to regulate the same gene the expression of which it is currently regulating. Generally, heterologous nucleic acid sequences are not endogenous to the cell or part of the genome in which they are present, and have been added to the cell, by infection, transfection, microinjection, electroporation, or the like. In some embodiments, "heterologous

- 11 -

nucleic acid constructs" contain a control sequence/DNA coding sequence combination that is the same as, or different from a control sequence/DNA coding sequence combination found in the native cell.

As used herein, "homology" refers to sequence similarity or identity, with identity being preferred. This homology is determined using standard techniques known in the art (*See e.g.*, Smith and Waterman, *Adv. Appl. Math.*, 2:482 (1981); Needleman and Wunsch, *J. Mol. Biol.*, 48:443 (1970); Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 (1988); programs such as GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, WI); and Devereux *et al.*, *Nucl. Acid Res.*, 12:387-395 (1984)).

The term "target site" is intended to mean a predetermined genomic location within a bacterial chromosome where integration of a DNA construct or a DNA library is to occur.

As used herein, the term "chromosomal integration" refers to the process whereby an exogenous nucleic acid sequence is introduced into the chromosome of a host cell (*e.g.*, *Bacillus*). The homologous sequences of the exogenous nucleic acid sequence align with homologous regions of the chromosome. Subsequently, the sequence between the homologous regions of the chromosomal sequence is replaced by the incoming exogenous sequence in a double crossover (*i.e.*, homologous recombination).

As used herein, the term "introduced" used in the context of inserting a nucleic acid sequence into a cell, means "transfection," "transformation," or "transduction," and includes reference to the incorporation of a nucleic acid sequence into a eukaryotic or prokaryotic cell where the nucleic acid sequence may be incorporated into the genome of the cell (*e.g.*, chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (for example, transfected mRNA).

As used herein, the terms "transformed," "stably transformed," and "transgenic" used in reference to a cell means the cell has a non-native (heterologous) nucleic acid sequence integrated into its genome or as an episomal plasmid that is maintained through two or more generations.

As used herein "an insertion DNA construct" or "insertion DNA cassette" is a DNA construct that includes a selectable marker gene which is flanked on both sides by a recombinase recognition site. A "recombinase recognition site" is a novel recombination site that facilitates directional insertion of nucleotide sequences into corresponding recombination sites at a predetermined genomic location (a target site) within the bacterial chromosome where the integration of a DNA fragment is to occur.

As used herein, the term "selectable marker" refers to a gene capable of expression in host cell which allows for ease of selection of those hosts containing an introduced nucleic acid or vector. Examples of such selectable markers include but are not limited to antimicrobials, (*e.g.*, kanamycin, erythromycin, actinomycin, chloramphenicol and tetracycline). Thus, the term "selectable marker" refers to genes that provide an indication that a host cell has taken up an exogenous polynucleotide sequence or some other reaction has occurred. Typically, selectable markers are genes that confer antimicrobial resistance or a metabolic advantage on the host cell to allow cells containing the

- 12 -

exogenous DNA to be distinguished from cells that have not received any exogenous sequence during the transformation.

As used herein, the terms "amplification" and "gene amplification" refer to a process by which specific DNA sequences are disproportionately replicated such that the amplified nucleic acid sequence becomes present in a higher copy number than was initially present in the genome. The term also refers to the introduction into a single cell of an amplifiable marker in conjunction with other gene sequences (*i.e.*, comprising one or more non-selectable genes such as those contained within an expression vector) and the application of appropriate selective pressure such that the cell amplifies both the amplifiable marker and the other, non-selectable gene sequences. The amplifiable marker may be physically linked to the other gene sequences or alternatively two separate pieces of DNA, one containing the amplifiable marker and the other containing the non-selectable marker, may be introduced into the same cell.

As used herein, the term "polymerase chain reaction" ("PCR") refers to the methods of U.S. Patent Nos. 4,683,195; 4,683,202, and 4,965,188, hereby incorporated by reference, which include methods for increasing the concentration of a segment of a polynucleotide or target sequence in a mixture of genomic DNA without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing and polymerase extension can be repeated many times (*i.e.*, denaturation, annealing and extension constitute one "cycle"; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be "PCR amplified".

As used herein, the term "PCR product," refers to the resultant mixture of compounds after two or more cycles of the PCR steps of denaturation, annealing and extension are complete. These terms encompass the case where there has been amplification of one or more segments of one or more target sequences. The term double stranded amplified products includes PCR products.

As used herein, the term "restriction enzymes" refers to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

With PCR, it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (*e.g.*, hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection;

- 13 -

incorporation of ^{32}P -labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment). In addition to genomic DNA, any oligonucleotide or polynucleotide sequence can be amplified with the appropriate set of primer molecules. In particular, the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications.

As used herein, "host cell" refers to a cell that has the capacity to act as a host and expression vehicle for an introduced DNA (exogenous) sequence according to the invention.

As used herein the term "expression" refers to the process by which a polypeptide is produced based on the nucleic acid sequence of a gene. The process includes both transcription and translation.

A "range of expression levels" means the expression of a gene of interest obtained from a library of bacterial clones transformed with PCR generated DNA libraries. In one embodiment, the level of expression in a clone library will range from 1 to 500%, compared to the expression of a control which includes a precursor or native promoter and regulatory region when grown under essentially the same conditions.

"Optimal expression" refers to the cumulative conditions that provide an optimal level of gene expression for a particular coding region. Under certain laboratory conditions, optimal expression means a lower level of gene expression and under other conditions, optimal expression means a higher level of gene expression that can coexist in a cell in situations where, under certain conditions the expressed gene or product produced therefrom would be detrimental to the viability of the cells or have an adverse effect upon the cells.

"Isolated" as used herein refers to a nucleic acid or polypeptide that is removed from at least one component with which it is naturally associated.

The term "comprises and its cognates are used in their inclusive sense: that is equivalent to the term including and its cognates.

"A", "an" and "the" include plural references unless the context clearly dictates otherwise.

Preferred Embodiments of the Invention

Promoter sequences useful for creating artificial promoters according to the invention include the precursor promoters listed in Table 1 below. Figure 4 illustrates the sequence of some of these precursor promoters including the -35 box, -10 box and linker region. All promoters in the table are characterized with respect to the beta-lactamase promoter Pbla and promoter strengths are given in "Pbla-units". (Deuschle et al., *EMBO Journal* 5(11):2987-2994 (1986)).

In general, promoters useful in the invention include promoter sequences of between 200 to 20 base pairs (bp), preferably 150 to 25 bp, more preferably between 100 to 30 bp and most preferably between 50 to 30 bp upstream from the transcription start site (+1). The shorter sequences (between 50 to 30 bp) are most preferred because DNA libraries may be created more easily within a single degenerated oligonucleotide with the shorter sequences. Therefore in a preferred embodiment, a short sequence of the promoters as disclosed in Figure 4 would be used to

- 14 -

obtain artificial promoters according to the invention. These preferred sequences would include about 50 to 30 bp starting at about the transcriptional start site (+ 1) of said promoters.

Table 1

PROMOTER	Source	Relative Activity	SEQ ID NO.
β -lactamase (bla)	<i>E. coli</i> vector	1	14
PConsensus (con)	Synthetic DNA	4	13
PTac I (Trc)	Hybrid of 2 promoters	17	2
PLacUV5	Mutant of Lac	3.3	12
Plac	<i>E. coli lacZ</i> gene	5.7	1
PL	Phage λ	37	11
PA1	Phage T7	22	8
PA2	Phage T7	20	9
PA3	Phage T7	76	10
PJ5	Phage T5	9	7
PG25	Phage T5	19	6
PN25	Phage T5	30	5
PD/E20	Phage T5	56	4
PH207	Phage T5	55	3

5

Additional promoters useful in the invention are disclosed in Sommer et al., (2000) *Microbiol.* 146:2643 – 2653, wherein the sequence of Ptac and variants containing 1 or 2 base pair changes are taught. In one embodiment a preferred precursor promoter is a trc promoter (Ptrc). The -35 box (TTGACA) and the -10 box (TATAAT) is the same as Ptac. However, the linker region of Ptrc includes 17bp as compared to 16 bp for Ptac. There is an addition of a "C" between nucleotides -18 and -10 of Ptac. (Russell and Bennett, (1982) *Gene*: 20:231 and Amann et al., (1983) *Gene* 25:167 - 178).

A further useful promoter is the glucose isomerase promoter P_{GI} . This promoter is also known in the literature as a xylose isomerase promoter and reference is made to Amone et al., (1989) *Appl. Microbiol. Biotechnol.* 30:351 – 357. The P_{GI} comprises the following
 GCCCTTGACA ATGCCACATCCTGAGCA AATAAT TCAACCACTA ATTGTGAGCGGATAACA
 (SEQ ID NO. 15), wherein the -35 box is represented by TTGACA, the -10 box is represented by AATAAT and the +1 transcription start site is A.

In addition to the above promoters, a variety of precursor promoters can be utilized in the practice of the present invention. In some cases, strong promoters tend to be overexpressed to the detriment of the host cell viability. Cells use a limited set of signals to engage the transcriptional

20

machinery and transcribe a gene. Bacteria such as *E. coli*, uses a core RNA polymerase and several sigma subunits to recognize different type of promoters (deHaseth et al. 1998. *J. Bact.* 180: 3019-3025. The *E. coli* genes required for fast growth are mainly under the control of the sigma factor coded by the *rpoD* gene. The most obvious components of a RpoD-dependent promoter are the -35 and -10 regions that contain variations of the consensus sequences TTGACA and TATAAT respectively. The promoter region contains 2 other components that affect promoter strength in a subtler manner: the upstream (Gourse et al., 2000. *Mol. Microbiol.* 37: 687-695) and the spacer regions (Burr et al. (2000) *NAR* 28: 1864-1870). The contribution of each one of these 2 elements varies depending on how similar the -35 and -10 region are to the consensus.

A precursor promoter used to obtain a library of artificial promoters as described herein may be determined by various exemplary methods. While not wanting to be limited, in one embodiment, sequencing of a particular host genome may be performed and putative promoter sequences identified using computerized searching algorithms. For example, a region of a genome may be sequenced and analyzed for the presence of putative promoters using Neural Network for Promoter Prediction software, NNPP. NNPP is a time-delay neural network consisting mostly of two feature layers, one for recognizing TATA-boxes and one for recognizing so called "initiators", which are regions spanning the transcription start site. Both feature layers are combined into one output unit. Further identification of precursor promoter sequences can be identified by examination of putative promoter sequences identified in a genome of a host cell using homology analysis. For example, by using BLAST. These putative sequences may then be cloned into a cassette suitable for preliminary characterization in *E. coli* and/or direct characterization in *E. coli*.

In another embodiment, identification of consensus promoter sequences can be identified by examination of the family of genomes and putative promoter sequences identified in the genome in question using homology analysis. For example, a homology study of a family of genomes may be performed and analyzed for the presence of putative consensus promoters using BLAST. These putative promoter sequences may then be cloned into a cassette suitable for preliminary characterization in *E. coli*.

An artificial promoter according to the invention will comprise at least one modification to a nucleotide in a precursor promoter. In one embodiment the modification will be to a nucleotide positioned in the -35 consensus region. This modification may include a modification to one or more nucleotides at a position equivalent to a nucleotide at the -30, -31, -33, -34, -35, and/or -36 position of a precursor promoter. Preferably the modification will be of one or two nucleotides, and preferably the modification will be a substitution of one nucleotide or two nucleotides. When two positions are to be modified, four positions will be conserved, and when one position is modified, five positions will be conserved. In another embodiment the modification will include a modification to the nucleotide represented by position -30 and/or a change to a position corresponding to -35.

In preferred embodiments, an artificial promoter is obtained from a precursor promoter having a -35 box represented by the following sequences, TTGACA, TTGCTA, TTGCTT, TTGATA, TTGACT, TTTACA and TTCAAA. Particularly preferred -35 consensus regions from precursor

- 16 -

promoters are TTTACA and TTGACA. As a non-limiting example when TTGACA is the -35 box of a precursor promoter, the nucleotide at position -30 is A and it may be substituted with a T, G or C nucleotide, the nucleotide at position -31 is C and it may be substituted with a A, T or G nucleotide; the nucleotide at position -32 is A and it may be substituted with a T, G or C nucleotide; the nucleotide at position -33 is G and it may be substituted with a A, T, or C nucleotide; the nucleotide at position -34 is T and it may be substituted with a A, G or C nucleotide; and the nucleotide at position -35 is T and it may be substituted with a A, G or C nucleotide.

In another embodiment, the modification will be in the -10 consensus region. This modification may include a modification to one or more nucleotides at a position corresponding to the -7, -8, -9, -10, -11, and/or -12 position of a precursor promoter. Preferably the modification will be in one or two nucleotide positions. In a particularly preferred embodiment, the precursor promoter will include the following sequences of the -10 box, TAAGAT, TATAAT, TATACT, GATACT, TACGAT, AATAAT, TATGTT and GACAAT. Particularly preferred are the sequences TATAAT, TATGTT, AATAAT and TAAGAT and most preferred are TATAAT and AATAAT. In one particular embodiment, the precursor promoter is the trc promoter and most particularly the 50 to 30 bp sequence upstream of the +1 transcription start site and the artificial promoter will include at least one modification to a nucleotide in the -10 box represented by TAAGAT. For example, since the nucleotide at position -7 is T, it may be substituted with a C, G or A nucleotide; since the nucleotide at position -8 is A, it may be substituted with a C, G or T nucleotide; since the nucleotide at position -9 is G, it may be substituted with a C, T or A; since the nucleotide at position -10 is A, it may be substituted with a T, C or G nucleotide; since the nucleotide at position -11 is A, it may be substituted with a T, C or G nucleotide; and since the nucleotide at position -12 is T, it may be substituted with a C, G or T nucleotide.

In some embodiments of the invention, both the -35 box and the -10 box of the precursor promoter will have modifications. In one embodiment, the modification will include one nucleotide in each consensus region, and in a further embodiment the modification will include two nucleotides in each consensus region. In another embodiment a modification will include a modification to the -35 box represented by TTGACA and a modification to the -10 box represented by AATAAT. In another embodiment the modification will include a modification to the -35 box represented by TTGACA and a modification to the -10 box represented by TATAAT.

The linker sequence of a precursor promoter may also be modified to obtain an artificial promoter according to the invention. The precursor linker sequence may include deletions, substitutions or insertions. Preferably the linker sequence is between 14 and 20 base pairs in length. The length of the linker sequence may be modified to optimize expression by performing deletion analysis, such as by site directed mutagenesis to create sequential deletions in the precursor promoter. The linker sequence or the precursor promoter may be modified in length to include 16 base pairs, 17 base pairs, 18 base pairs, 19 base pairs or 20 base pairs.

In one embodiment, modified DNA sequences in the precursor promoter are generated by using a degenerated oligonucleotide in accordance with well know techniques. In a preferred

- 17 -

embodiment, the artificial promoters will comprise 30 to 50 bp upstream of the transcription site (+1) so that the promoter could be contained within an oligonucleotide and the library of promoters created by degeneration of the oligonucleotide.

Promoter strength can be quantified using *in vitro* methods that measure the kinetics of binding of the RNA polymerase to a particular piece of DNA, and also allows the measurement of transcription initiation (Hawley D.K et al., Chapter 3: in: PROMOTERS: STRUCTURE AND FUNCTION. R.L/ Rodriguez and M.J. Chamberlin eds. Praeger Scientific. New York). *In vivo* methods have been used also to quantify promoter strength. In this case, the approach has been to fuse the promoter to a reporter gene and the efficiency of RNA synthesis measured.

To create DNA libraries which comprise a library of artificial promoters, a first degenerated oligonucleotide comprising a nucleic acid sequence homologous to a first end, preferably the 3' end, of an insertion DNA construct, a promoter as described above, and a nucleic acid sequence homologous to the downstream region of the transcription start site of a precursor or native promoter is mixed with both i) a second oligonucleotide which comprises a nucleic acid sequence homologous to an upstream region of the precursor or native promoter of a chromosomal gene of interest and a nucleic acid sequence homologous to a second end, preferably the 5' end, of the insertion DNA construct, and ii) an insertion DNA construct in an amplification reaction, preferably a PCR reaction to obtain double stranded amplified products comprising artificial promoters.

In a preferred embodiment, an insertion DNA construct is carried on a plasmid, preferably on a R6K plasmid and comprises an antibiotic resistance gene flanked on both sides by a recombinase recognition site. (Datsenko and Warner (2000) *Proc. Natl. Acad. Sc.* 97:6640-6645). While any desired selective marker can be used, antibiotic resistant markers (Anb^R) are most useful. These include but are not limited to, Cm^R, Km^R and Gm^R. Preferably, the recombinase recognition sites are the same. Recombinase sites are well-known in the art and generally fall into two distinct families based on their mechanism of catalysis and reference is made to Huang et al., (1991) *Nucleic Acids Res.* 19:443 and Nunes-Duby et al., (1998) *Nucleic Acid Res.* 26:391 - 406.

A preferred recombination system is the *Saccharomyces* Flp/FRT recombination system, which comprises a Flp enzyme and two asymmetric 34 bp FRT minimum recombination sites (Zhu et al., (1995) *J. Biol. Chem.* 270:11646 - 11653). A FRT sites comprises two 13 bp sequences, inverted and imperfectly repeated, which surround an 8 bp core asymmetric sequence where crossing-over occurs. The FLP-dependent intramolecular recombination between two parallel FRT sites results in excision of any intervening DNA sequence as a circular molecule producing two recombination products, each containing one FRT site (Huffman et al. (1999) *J. Mol. Biol.* 286: 1 - 13).

In general, nucleic acid sequences homologous to downstream regions or upstream regions may include from 2 - 150 bp, preferably 5 - 100 bp, more preferably 5 - 50 bp and also 10 - 40 bp. In specific embodiments a nucleic sequence homologous to the downstream transcription start site of the precursor or native promoter or a nucleic acid sequence homologous to an upstream region of the precursor promoter of a chromosomal gene of interest may include about 5 to 100 base pairs

- 18 -

and also 5 to 50 base pairs. The nucleic acid homologous to a 5' or 3' end of the insertion DNA construct may include about 10 to 40 base pairs and preferably about 2 to 25 base pairs. An upstream region of the precursor promoter means a segment upstream (5') of the -35 consensus sequence.

5 In further embodiments of the invention a RBS, downstream of the precursor promoter region, may be modified. Preferred RBSs, which may be modified include the sequences selected from the following: AGGAAA, (SEQ ID NO. 30), AGAAAA (SEQ ID NO. 31), AGAAGA (SEQ ID NO. 32), AGGAGA (SEQ ID NO. 33), AAGAAGGAAA (SEQ ID NO. 34), AAGGAAAA (SEQ ID NO. 35), AAGGAAAG (SEQ ID NO. 36), AAGGAAAU (SEQ ID NO. 37), AAGGAAAAA (SEQ ID NO. 38),
 10 AAGGAAAAG (SEQ ID NO. 39), AAGGAAAAAU (SEQ ID NO. 40), AAGGAAAAAA (SEQ ID NO. 41), AAGGAAAAAG (SEQ ID NO. 42), AAGGAAAAAU (SEQ ID NO. 43), AAGGAAAAAAA (SEQ ID NO. 44), AAGGAAAAAAG (SEQ ID NO. 45), AAGGAAAAAAU (SEQ ID NO. 46), AAGGAAAAAAA (SEQ ID NO. 47), AAGGAAAAAAG (SEQ ID NO. 48), AAGGAAAAAAU (SEQ ID NO. 49), AAGGAAAAAAA (SEQ ID NO. 50), AAGGAAAAAAG (SEQ ID NO. 51),
 15 AAGGAAAAAAU (SEQ ID NO. 52), AAGGAAAAAAA (SEQ ID NO. 53), AAGGAAAAAAG (SEQ ID NO. 54), AAGGAGGAAA (SEQ ID NO. 55), and AAGGAAAAAAU (SEQ ID NO. 56). Most preferred RBS include AGGAAA, (SEQ ID NO. 30), AGAAAA (SEQ ID NO. 31), AGAAGA (SEQ ID NO. 32), AGGAGA (SEQ ID NO. 33), and AAGGAGGAAA (SEQ ID NO. 55). The modified RBS may include substitution, deletion or insertion
 20 of anyone of the base pairs comprising the RBS.

To obtain DNA libraries comprising modified RBS libraries, a oligonucleotide comprising a nucleic acid fragment homologous to a downstream region of the -10 box of a promoter or artificial promoter, a modified RBS, and a nucleic acid fragment homologous to the 5' end of the
 25 chromosomal gene of interest which includes the start codon, is mixed with the double stranded amplified products comprising artificial promoters as described above and under similar PCR reactions. The homologous nucleic acid fragments may comprise from 2 to 100 base pairs and preferably from 2 to 50 base pairs. In other embodiments the (XTG) start codon of the gene of interest may be modified. These modifications may include X = A, T, G, depending on the native start codon in the gene of interest.

30 In other embodiments of the method described herein a stabilizing mRNA sequence may be incorporated into an oligonucleotide. The oligonucleotide may comprise an artificial promoter, a modified ribosome binding or both. The stabilizing sequences are preferably inserted between the RBS and the transcription start site.

Stabilizing mRNA sequence are well known in the art and reference is made to Carrier et al.
 35 (1999) *Biotechnol. Prog.* 15:58 – 64. Preferred mRNA stabilizing sequences include the sequences GGTGAGTTATCTCGAGTGAGATATTGTTGACG, (SEQ ID NO. 63); GGTGACTTATCTCGAGTGAGATATTGTTGACG, (SEQ ID NO. 64); CCTGAGTTATCTCGAGTGAGATATTGTTGACG, (SEQ ID NO. 65); GCTGAGTTATCTCGAGTGAGATATTGTTGACG, (SEQ ID NO. 66);

- 19 -

CGTCGAGTTATCTCGAGTGAGATATTGTTGACG, (SEQ ID NO.67);
GGTGGAGTTATCTCGAGTGAGATATTGTTGACG, (SEQ ID NO. 68) and
GCTGGACTTATCTCGAGTGAGATATTGTTGACG, (SEQ ID NO. 69). In a preferred embodiment
the stabilizing sequence is SEQ ID NO. 67. The double stranded amplified products may also
5 include modified start codons of a gene of interest.

The double stranded amplified products which comprise artificial promoters, modified
ribosome binding sites, modified start codons, stabilizing mRNA sequences and combinations
thereof, according to the invention may be used individually and introduced into a host cell.
Additionally, the double stranded amplified products may be used in a DNA library wherein said
10 library comprises one or more of a library of artificial promoters, a library of modified ribosome
binding sites, a library of modified start codons and which may or may not include stabilizing mRNA
sequences. The DNA libraries are introduced into bacterial host cells wherein they replace the
chromosomal regulatory regions of a gene of interest. Preferably the double stranded amplified
products are integrated into the host cell chromosome. Flanking homologous regions of the double
15 stranded amplified products replace homologous regions at a target site in a gene sequence of
interest in a host chromosome. In a preferred embodiment, the integration of the PCR products is a
stable and non-reverting integration. Preferably replacement is by a double crossover (i.e.,
homologous recombination). The introduced PCR products may create a library of bacterial cells
having a range of expression levels for a gene of interest.

20 The method as disclosed herein is not limited to expression of any particular gene or group
of genes (an operon), but is intended to be broadly applicable to many different genes or operons.
In one preferred embodiment, the artificial promoters or other regulatory DNA constructs according
to the invention will be operably linked to a coding sequence that was heterologous to a precursor
promoter, and in another embodiment the artificial promoters or other regulatory DNA constructs will
25 be operably linked to a coding sequence that was homologous to the precursor promoter. Further
the coding sequence may be heterologous or endogenous to the host cell transformed according to
the invention.

In some embodiments, the gene encodes therapeutically significant proteins or peptides,
such as growth factors, hormones, cytokines, ligands, receptors and inhibitors, as well as vaccines
30 and antibodies. A gene may also encode commercially important proteins or peptides, such as
enzymes (e.g., proteases, amylases, glucoamylases, dehydrogenases, esterases, cellulases,
galactosidases, oxidases, reductases, kinases, xylanases, laccases, phenol oxidases, chitinases,
glucose oxidases, catalases, phytases, isomerases, phosphatases, and lipases). In further
embodiments the gene of interest encodes global regulators; transporter proteins, such as glucose
35 and/or DKG permeases, and enzymes from primary and secondary metabolism, such as tpi and nuo
which code for triose phosphate isomerase and NADH dehydrogenase, respectively.

In one embodiment, the host cell is a bacterial cell such as a gram positive bacteria. In
another embodiment the host cell is a gram-negative bacteria. In some preferred embodiments, the
term refers to cells in the genus *Pantoea*, the genus *Bacillus* and *E. coli* cells.

- 20 -

As used herein, "the genus *Bacillus*" includes all members known to those of skill in the art, including but not limited to *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*, *B. circulans*, *B. lautus*, and *B. thuringiensis*. It is recognized that the genus *Bacillus* continues to
5 undergo taxonomical reorganization. Thus, it is intended that the genus include species that have been reclassified, including but not limited to such organisms as *B. stearothermophilus*, which is now named "*Geobacillus stearothermophilus*." The production of resistant endospores in the presence of oxygen is considered the defining feature of the genus *Bacillus*, although this characteristic also applies to the recently named *Alicyclobacillus*, *Amphibacillus*, *Aneurinibacillus*, *Anoxybacillus*,
10 *Brevibacillus*, *Filobacillus*, *Gracilibacillus*, *Halobacillus*, *Paenibacillus*, *Salibacillus*, *Thermobacillus*, *Ureibacillus*, and *Virgibacillus*.

As used herein, "the genus *Pantoea*" includes all members known to those of skill in the art, including but not limited to *P. agglomerans*, *P. dispersa*, *P. punctata*, *P. citrea*, *P. terreus*, *P. ananas* and *P. sterartii*. It is recognized that the genus *Pantoea* continues to undergo taxonomical
15 reorganization. Thus, it is intended that the genus include species that have been reclassified, including but not limited to such organisms as *Erwinia herbicola*.

One skilled in the art are well aware of methods for introducing polynucleotides into host cells and particularly into *E. coli*, *Bacillus* and *Pantoea* host cells. General transformation techniques are disclosed in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY Vol. 1, eds. Ausubel et al. John Wiley
20 & Sons Inc, (1987) Chap. 7. and Sambrook, J., et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press (1989). Reference is also made to Ferrari et al., Genetics pgs 57 -72 in Hardwood et al. Ed. BACILLUS, Plenum Publishing Corp. 1989; Chang et al., (1979) *Mol. Gen. Genet.* 168:11 - 15; Smith et al., (1986) *Appl. and Env. Microbiol.* 51:634 and Potter, H. (1988) *Anal Biochem* 174:361 - 373 wherein methods of transformation, including electroporation,
25 protoplast transformation and congression; transduction and protoplast fusion are disclosed. Methods of transformations are particularly preferred.

Methods suitable for the maintenance and growth of bacterial cells is well known and reference is made to the Manual of Methods of General Bacteriology, Eds. P. Gerhardt et al., American Society for Microbiology, Washington, DC (1981) and T.D. Brock in Biotechnology: A
30 Textbook of Industrial Microbiology 2 ed. (1989) Sinauer Associates, Sunderland MA.

The transformed host cells are selected based on the phenotype response to a selectable marker which was provided in an insertion DNA construct. In some embodiments the selectable marker may be excised out of the host cell. (Cherepanov et al. (1995) *Gene* 158:9 - 14).

Additionally transformants may be analyzed to verify the integration of the regulatory DNA
35 constructs, such as artificial promoters using various techniques. The regulatory DNA constructs including artificial promoters may be PCR verified using oligonucleotides outside the recombinase region. In one example the size of the PCR product obtained from the artificial promoter is compared to the size of the PCR product obtained from the reference promoter on an agarose gel. The regulatory DNA constructs may be verified by digesting the PCR product obtained from the artificial

- 21 -

promoter with a restriction enzyme that is unable to digest the artificial promoter and that is able to digest the reference promoter. The regulatory DNA constructs may also be verified by evaluating gene expression and production. Many assays are known for measuring enzyme activity. For example beta-galactosidase is the enzyme produced by the lacZ gene, and the activity of this enzyme may be determined by the assay disclosed in Miller, J.H., A SHORT COURSE IN BACTERIAL GENETICS. Cold Spring Harbor Laboratory Press, 1992,

Additionally, the artificial promoter region and other regulatory regions in a host cell may be sequenced by means well known in the art. (Maxam et al., (1977) PNAS USA 74:560 – 564)

Transformed host cells according to the invention may have expression levels of a gene of interest which may be higher or lower than the expression level of the coding region of the gene in a parent control. In one embodiment the level of gene expression in a transformed host will be between about 1 to 500%, between about 1 to 250%, between about 5 to 200%, between about 10 to 150% and between about 10 to 100% of the level of expression of the same gene in the corresponding parent. Also about 5%, 15%, 25%, 35%, 45%, 55%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 120%, 140%, 160%, 180% and 200% the expression level of a corresponding parent.

Using a DNA library according to the invention, which includes an artificial promoter library, a modified RBS library, a mRNA stabilizing sequence library, or a start codon library or combinations thereof to create a population of bacterial cells having varying levels of expression of a gene of interest, is particularly useful in a metabolic engineering pathway framework.

A metabolic pathway is a series of chemical reactions that either break down a large molecule into smaller molecules (catabolism) or synthesize more complex molecules from smaller molecules (anabolism). Most of these chemical reactions are catalyzed by a number of enzymes. In many metabolic pathways there are rate-limiting enzymatic steps which serve to regulate the pathway. For example, in the glycolytic pathway wherein glucose is converted to pyruvate and ATP, phosphofructokinase is considered a key enzyme in regulation and in the pentose phosphate pathway wherein NADPH and ribose-5-phosphate are generated, glucose-6-phosphate dehydrogenase and fructose 1,6-diphosphatase are considered key enzymes.

In order to be commercially viable a chemical or protein must be capable of being produced and recovered in large quantities in an organism with low cultivation cost. Many industrial bioprocesses utilize whole-cell fermentation techniques. In many instances, the use of an isolated enzyme system is too expensive or impractical. Many enzymes, such as dehydrogenases that may be utilized to carry out chiral synthesis of pharmaceutical intermediates, require co-factors such as NAD(P) for their reactions. Cofactors are utilized stoichiometrically during the reaction and must be repeatedly added to the reaction mixture or the reaction must regenerate the cofactor. A whole-cell system provides an alternative for many of these enzymes. Other enzymes may be membrane-bound or require complex subunit or multi-enzyme complexes (such as cytochrome P-450s), allowing for simpler implementation using a whole-cell system. Finally, the synthesis of complex

molecules such as steroids, antibiotics, and other pharmaceuticals may require complicated and multiple catalytic pathways.

In an isolated system, each step in a particular metabolic pathway would need to be engineered. In contrast, the organism utilized in a whole cell system provides each of the required pathways. However, the use of certain promoters may incur problems, such as being too strong. As a result, overexpression of a particular gene may occur and be detrimental to a cell. The cell's viability can thus be reduced and the production time may be limited.

The methods provided herein are utilized to provide a library of regulatory DNA constructs such as a library of modified promoters, a library of modified RBS and, a library of modified start codons, which may include stabilizing mRNA sequences to be introduced into bacterial host cells which results in a population of transformed cells having a range of gene expression. The range of gene expression is useful because it allows the selection of specific bacterial clones having an optimum level of expression but still maintaining cell viability (e.g. the flux production of the desired end product relative the viability of the host cell in sustaining the desired level of production or sustaining the desired level of production). In certain embodiments the optimum level of expression of a gene will be high and in other embodiments the optimum level of gene expression will be low. In one embodiment, the level of expression of a gene of interest in a clone library may range from -100 to +500%, also - 50 to 150% and -80 to 100%. For example, the expression of a gene of interest in certain clones of a library may be 100% less than the expression of the gene in a corresponding parent. Also, the expression of the gene of interest in certain clones may be 500% greater than the expression of the same gene in the corresponding parent.

A direct advantage of this method is that a bacterial clone may be selected based on the expression level obtained from the DNA libraries and then be ready for use in a fermentation process whereby cell viability is not negatively affected by expression of the gene of interest.

The following Examples are for illustrative purposes only and are not intended, nor should they be construed as limiting the invention in any manner. Those skilled in the art will appreciate that variations and modifications can be made without violating the spirit or scope of the invention.

EXAMPLES

The *E. coli* strain MG1655 having ATCC No. 47076 was utilized to create a library of bacterial clones comprising a library of artificial promoters, a library of mRNA stabilizing sequences and a library of modified RBSs.

EXAMPLE 1 - Creation of a library of *Escherichia coli* clones with different levels of expression of a chromosomal gene by deleting a regulator and replacing the natural promoter by PCR generated artificial promoters of different strength

This example describes the deletion of *lacI* encoding a repressor and the replacement into the *Escherichia coli* genome of the natural *lacZ* (encoding the β -galactosidase) promoter by PCR generated artificial promoters of different strength.

a) Design of the oligonucleotides for the *lacZ* promoter replacement.

Oligonucleotides (*lacZF* and degenerated *lacZR*) were designed to amplify by PCR a cassette containing an 79 bp sequence homologous to the 5' of the *lacI* gene, a chloramphenicol-resistance encoding gene (*cat*) flanked by baker yeast *FRT* sites, a library of three artificial GI promoter sequences (Figure 6) and a 40 bp sequence homologous to the downstream region of the +1 transcription start site of the natural *lacZ* promoter.

The degenerated *lacZR* primers were 100 nucleotides long and included the entire sequence from the +1 of the transcription start site to the ATG of *lacZ* (365529 to 365567).

10 *LacZR* oligonucleotide:

TAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTAGTGGTTGAATTATTTGCTCAGGATG
TGGCATHGTCAAGGGCATATGAATATCCTCCTTAG wherein H is A, C or T (SEQ ID NO. 57)

The GI promoters from 4 bp upstream of the -35 to 8 bp downstream the -10, were degenerated at the last base of the -35 (TTGACA, TTGACT and TTGACG) to create the diversity.

15 The priming site for pKD3 (Datsenko and Wanner, (2000) *PNAS*, 97: 6640-6645) an R6K plasmid containing the *cat* gene flanked by two *FRT* sites.

The *lacZF* primer is 100 nucleotides long (SEQ ID NO. 58) and contains: 79 bp of sequence (from 366734 to 366675) at the 5' end of the *lacI* gene and the priming site for pKD3

20 *LacZF* oligonucleotide:

GTGAAACCAGTAACGTTATACGATGTCGCAGAGTATGCCGGTGTCTCTTATCAGACCGTTTCCC
GCGTGGTGAACCAGGGTGTAGGCTGGAGCTGCTTCG (SEQ ID NO. 58)

b) Amplification and purification of the GI promoter replacement cassettes.

25 Primers *lacZF* and *lacZR* were used to amplify the library of promoter replacement cassettes using plasmid pKD3 as a template. The amplification used 30 cycles of 94°C for 2 minutes; 60°C for 30 sec; 72°C for 2 min using Taq polymerase as directed by the manufacturer (BioLabs, New England). The mixture of 1.15 kb PCR products were gel purified using the Qiaquick gel extraction kit (QIAGEN, Inc.).

30

c) Creation of the library of clones with different artificial promoter in from of the *lacZ* genes.

Transformants carrying Red Helper plasmid (pKD 46) (Datsenko and Wanner, supra) were grown in 20 ml SOB medium with carbenicillin (100 mg/l) and L arabinose (10mM) at 30°C to an OD_{550nm} of 0.6 and then made electrocompetent by concentration 100 fold and washed one time with ice water and twice with ice cold 10% glycerol. Electroporation was done using a Gene pulse (BioRad - model II apparatus 165-2106) with a voltage booster and 0.2 cm chamber according to manufactures instructions by using 50 µl of cells and 0.1 to 1.0 µg of the mixtures of purified PCR products (as described above). Shocked cells were added to 1 ml SOC medium incubated 2 hours at 30°C and then half of the cells were spread on agar to select Cm^R transformants. Xgal 40 mg/l

- 24 -

was added on the agar plates to evaluate the β galactosidase expression. If cells did not grow within 24 hours, the remainder were spread after standing overnight at 30°C.

d) PCR verification of the transformants.

5 Mutants were grown overnight on LB medium with 30 mg/l Cm. 1ml of culture was washed with ice cold water and the chromosomal DNA was recovered in the supernatant after heat treatment (5 min at 94°C) of the washed cells. The PCR was performed using the chromosomal DNA and a set of two oligonucleotides (LacseqF and LacseqR). The amplification was performed as disclosed above. A 1.6 PCR product was obtained.

10 LacseqF oligonucleotide
GGCTGCGCAACTGTTGGGAA (SEQ ID NO. 59)
LacseqR oligonucleotide
CATTGAACAGGCAGCGGAAAAG (SEQ ID NO. 60)

15 The PCR product was digested by ECORV (1U/ μ g of ECORV, 2 hrs at 37°C). The comparison of the digestion profile of the mutants (modified precursor) with the wild-type strain showed that the ECORV is absent when the promoter is replaced.

The sequence of the P_{GI} in the different clones was determined by sequencing the different 1.2 kb PCR products with the lacseqF primer. 50 μ l of column purified PCR products (Quiaquick, 20 Quiagen, Inc.) obtained from the chromosomal DNA of the mutants were used and sequenced by Genome Express (Meylan, France).

The organization of the GI *lacZ* promoter region in the three types of recombinant clones obtained is shown in figure 6. As expected, they only differ by one base pair in their -35 region and were named 1.6 GI *lacZ* for TTGACA, 1.5 GI *lacZ* for TTGACT and 1.20 GI *lacZ* for TTGACG.

25

e) β galactosidase activity

A 25 ml LB culture with Cm (30 mg/l) of the mutants was maintained for 5 hr at 37°C. The cells were centrifuged 10 min at 4000 g and resuspended in 300 μ l of B-PER Bacterial Protein Extraction Reagent (Pierce, Rockford). After 10 min of incubation on ice, the solution was 30 centrifuges 2 min at 12000g at 4°C to separate the soluble proteins from cell debris. The supernatant was used to evaluate the β galactosidase activity. The β galactosidase activity was measured using synthetic substrate ONPG (ortho-nitrophenyl β -D-galactopyranoside) according to the procedure of Miller, (1992) A SHORT COURSE IN BACTERIA GENETICS, Cold Spring Harbor Laboratory Press. The conditions of the reaction were, 37°C, pH 7.3, λ 410nm, light path 1 cm. (Figure 7)

35

f) Elimination of the antibiotic resistance gene:

pCP20 (Cherepanov et al., (1995) Gene: 158:9 - 14) is a plasmid that carries an ampicillin resistance marker, contains a temperature sensitive origin of replication and thermal induction of FLP synthesis. CmR mutants were transformed (pCP20) and ampicillin resistant transformants were

- 25 -

selected at 30°C. A few colonies were purified selectively at 43°C and then tested for loss of all antibiotic resistance. The majority lost the FRT flanked resistance gene and the FLP helper plasmid simultaneously.

5

EXAMPLE 2 - Creation of a library of *Escherichia coli* clones with different levels of expression of a chromosomal gene by replacing the natural promoter with the 1.6G1 and creating a library of RBS with PCR generated linear DNA fragments.

This example describes the deletion of *lacI* and the replacement into the *Escherichia coli* genome of the natural *lacZ* (encoding the β -galactosidase) promoters and RBS by a PCR generated artificial promoter and RBS with different binding capacities.

a) Design of the oligonucleotides to create a library of replacement cassettes to replace the native promoter and modify the RBS and the start codon.

15

Oligonucleotide lacZRT was designed to amplify by PCR when used with lacZF a cassette containing a 79 bp sequence homologous to the 5' of the *lacI* gene, a chloroamphenicol resistance encoding gene (*cat*) flanked by baker yeast FRT sites, the 1.6G1 promoter sequence (SEQ ID NO. 19) and a 40 bp sequence homologous to the downstream region of the +1 transcription start site of the natural *lacZ* promoter.

LacZRT oligonucleotide (SEQ ID NO. 70)

TAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTAGTGGTTGAATTATTTGCTCAGGATGTGGCATGTCAAGGGCATATGAATATCCTCTTAG

A degenerate oligonucleotide, lacZRBSR, was designed with a 60 bases region homologous to *lacZ* after the start codon and a 40 bases region homologous to the lacZRT oligonucleotide.

LacZRBS R oligonucleotide (SEQ ID NO. 61)

CAGGGTTTTCCCAGTCACGACGTTGTAACGACGGCCAGTGAATCCGTAATCATGGTCATAGCTGTYTYCTBYKWGAAATTGTTATCCGCTCACAATTA wherein B is T, C or G; K is T or G; Y is C or T; and W is A or T.

30

This oligonucleotide (SEQ ID NO. 61) is degenerated in the RBS sequence (AAGGAGGAAA, degeneration of the 1st base (A) by a T, 2nd base (A) by a C; 3rd base (G) by a A; 4th base (G) by an A or C; 7th base (G) by an A and the 9th base (A) by a G.

b) Amplification and purification of the replacement cassettes.

35

Primers lacZF and lacZRT were used to amplify by PCR the 1.6 G1 promoter replacement cassette using pKD3 as template DNA. The amplification used 30 cycles of 94°C for 2 minutes; 60°C for 30 sec; 72°C for 2 min using Taq polymerase as directed by the manufacturer (BioLabs, New England).

- 26 -

The lacZF and lacZRBSR primers were used to amplify the library of replacement constructs using the 1.6G1 promoter replacement cassette created above as a template. The amplification used 30 cycles of 94°C for 2 minutes; 60°C for 3 sec; 72°C for 2 min using Taq polymerase as directed by the manufacturer (BioLabs, New England). The 1.15 kb PCR products
 5 were gel purified using the Quiaquick gel extraction kit (QIAGEN, Inc.).

c) Creation of a library of *lacZ* expression levels in *Escherichia coli* by homologous recombination in the chromosome using replacement cassettes in the form of linear DNA.

Transformants carrying red helper plasmid (pKD 46) (Datsenko and Wanner, supra) were
 10 grown in 20 ml SOB medium with carbenicillin (100 mg/l) and L arabinose (10mM) at 30°C to an OD_{550nm} of 0.6 and then made electrocompetent by concentration 100 fold and washed one time with ice water and twice with ice cold 10% glycerol. Electroporation was done using a Gene pulse (BioRad - model II apparatus 165-2106) according to manufactures instructions by using 50 µl of cells and 0.1 to 1.0 µg of the mixtures of purified PCR products (as described above). Shocked cells
 15 were added to 1 ml SOC medium incubated 2 hours at 30°C and then half of the cells were spread on agar to select CmR transformants. Xgal 40 mg/l was added on the agar plates to evaluate the β galactosidase expression. If cells did not grow within 24 hours, the remainder were spread after standing overnight at 30°C.

20 d) PCR verification of the transformants.

Mutants were grown overnight on LB medium with 30 mg/l Cm. 1.0 ml of culture was washed with ice cold water and the chromosomal DNA was recovered in the supernatant after heat treatment (5 min at 94°C) of the washed cells. The PCR was performed using the chromosomal DNA and the two oligonucleotides, LacseqF and LacseqR as disclosed above in example 1.
 25 Amplification also followed the protocol of example 1. A 1.6kb PCR product was obtained. The PCR product was digested by ECORV (1U/µg of ECORV, 2 hrs at 37°C). The comparison of the digestion profile of the mutants with the wild-type strain showed that the ECORV site is absent when the promoter is replaced.

The sequence of the replacement cassette in the different clones was determined by
 30 sequencing the different 1.6 kb PCR products with the lacFprimer. 50 µl of column-purified PCR products (Quiaquick, Quiagen, Inc.) obtained from the chromosomal DNA of the mutants were used and sequenced by Genome Express (Meylan, France).

Eight of the recombinant clones were designated as indicated below and the organization of the upstream region of *lacZ* in each recombinant clone is A = CAAGGAGGAA ACAGCTATG (SEQ
 35 ID NO.22), B = CAAGAAGGAA ACAGCTATG (SEQ ID NO. 23), C = CACACAGGAA ACAGCTATG (SEQ ID NO. 24) , D = CTCACAGGAG ACAGCTATG (SEQ ID NO. 25), E = CTCACAGGAA ACAGCTATG (SEQ ID NO. 26), F = CACACAGAAA ACAGCTATG (SEQ ID NO. 27), G = CTCACAGAGA ACAGCTATG (SEQ ID NO. 28), and H = CTCACAGAAA ACAGCTATG (SEQ ID NO. 29).

- 27 -

As expected the transformants differed only by RBS and the range of expression among the different clones of the library was from 5.7 to 0.02 U/mg of protein (Figure 8).

Elimination of the antibiotic resistance gene was performed as disclosed in example 1.

5 EXAMPLE 3 - Creation of a library of *Escherichia coli* clones with different levels of expression of a chromosomal gene by both replacing the native promoter by the 1.6 GI promoter and introducing mRNA stabilizing structures using a library of PCR generated linear DNA fragments.

This example describes the deletion of *lacI* and the replacement into the *Escherichia coli* genome of the natural *lacZ* (encoding the β -galactosidase) promoter and the lac operator by PCR
10 generated artificial promoters of different strength and artificial mRNA stabilizing structures with different efficiencies.

a) Design of the oligonucleotides to create a library of replacement cassettes to replace the promoter and the lac operator by a library of artificial promoters and mRNA stabilizing structures.

15 To generate broader *lacZ* expression level, a library of replacement cassettes was designed to remove *lacI*, the natural *lacZ* promoter and the lac operator and replace them by the 1.6 GI promoter and a library of mRNA stabilizing structure. For this purpose, a degenerate oligonucleotide, lacZmRNA, was designed with a 43 base region homologous to *lacZ* downstream the RBS site, 34 bases of mRNA stabilizing structure and a 23 bases region homologous to the lacZRT
20 oligonucleotide upstream the +1 of transcription. This oligonucleotide is degenerated in the mRNA stabilizing sequence.

LacZmRNA R oligonucleotide (SEQ ID NO. 62)

CGACGGCCAGTGAATCCGTAATCATGGTCATAGCTGTTTCCTCCTTCGTCAACAATATCTCACT
CGAGATAASTCGASSTAGTGGTTGAATTATTTGCTCAGG, wherein S is C or G.

25 If lacF and lacmRNA are used in a PCR reaction with the promoter replacement cassette (generated by PCR using the primers lacZF and lacZRT (SEQ ID NO. 70) as template DNA, a new library will be obtained with *lacI* deleted, the promoter replaced and the mRNA stabilizing structure introduced.

30 b) Amplification and purification of the replacement cassettes:

Primers lacF and lacZmRNA were used to amplify the library of replacement cassettes using the 1.6 GI promoter replacement cassette created in example 2 as template DNA. Amplification followed the procedures of example 1. The 1.15 kb PCR products were purified by agarose gel electrophoresis followed by QIAquick gel extraction Kit (QIAGEN).

35

c) Creation of a library of *lacZ* expression level in *Escherichia coli* by homologous recombination in the chromosome using replacement cassettes in the form of linear DNA:

Transformants carrying Red Helper plasmid (pKD 46) (Datsenko and Wanner, *supra*) were grown in 20 ml SOB medium with carbenicillin (100 mg/l) and L arabinose (10mM) at 30°C to an OD

- 28 -

550nm of 0.6 and then made electrocompetent by concentration 100 fold and washed one time with ice water and twice with ice cold 10% glycerol. Electroporation was done using a Gene pulse (BioRad - model II apparatus 165-2106) with a voltage booster and 0.2 cm chambers according to manufactures instructions by using 50 µl of cells and 0.1 to 1.0 µg of the purified PCR products (as described in b) above). Shocked cells were added to 1 ml SOC medium incubated 2 hours at 30°C and then half of the cells were spread on agar to select Cm^R transformants. Xgal 40 mg/l was added on the agar plates to evaluate the β galactosidase expression. If cells did not grow within 24 hours, the remainder were spread after standing overnight at 30°C.

10 d) PCR verification of the transformants.

Mutants were grown overnight on LB medium with 30 mg/l Cm. 1.0 ml of culture was washed with ice cold water and the chromosomic DNA was recovered in the supernatant after heat treatment (5 min at 94°C) of the washed cells.

The PCR was performed using the chromosomic DNA and a set of two oligonucleotides, LacseqF and LacseqR as disclosed above in example 1. Amplification also followed the protocol of example 1. A 1.6kb PCR product was obtained. The PCR product was digested by ECORV (1U/µg ECORV, 2 hrs at 37°C). The comparison of the digestion profile of the mutants with the wild-type strain showed that the ECORV site is absent when the promoter is replaced.

The sequence of the replacement cassette in the different clones was determined by sequencing the different 1.6 kb PCR products with the lacFprimer. 50 µl of column-purified PCR products (Qulaquick, Qulagen, Inc.) obtained from the chromosomic DNA of the mutants were used and sequenced by Genome Express (Meylan, France).

The organization of the upstream region of lacZ of the recombinant clones is shown in Figure 9. As expected the range of expression among the different clones of the library was from 4.1 to 18.4 U/mg protein.

EXAMPLE 4 - Creation of a library of *Escherichia coli* clones with different artificial promoters, modified start codons and modified RBS using a library of PCR generated linear DNA fragments.

This example describes the deletion of *lacI* and the replacement into the *Escherichia coli* genome of the natural *lacZ* (encoding the β-galactosidase) promoter, RBS and start codon by PCR generated artificial promoters of different strength, RBS with different binding capacity and start codons of different efficiency.

a) Design of the oligonucleotides for the *lacZ* promoter replacement.

To generate broader *lacZ* expression level, a library of replacement cassettes was designed to remove *lacI*, replace the promoter and modify the RBS. A degenerate oligonucleotide in RBS and in the start codon, lacZRBSR2 was designed with a 60 base region homologous to *lacZ* after the start codon and a 40 base region homologous to the *lacR* oligonucleotide.

- 29 -

LacZRBS R2 oligonucleotide (SEQ ID NO. 71)

CAGGGTTTTCCCAGTCACGACGTTGTAAACGACGGCCAGTGAATCCGTAATCATGGTCAHAG
CTGTYTYCTBYKWGAAATTGTTATCCGCTCACAATTA wherein B is T,C or G; H is A, T or C; K is
T or G; Y is C or T; and W is A or T.

5

b) Amplification and purification of the P_{GI} replacement cassettes.

Primers lacZF and lacZR were used to amplify the library of promoter replacement cassettes using plasmid pKD3 as a template as described in example 1. Primers LacZF and LacZRSB2R were used to amplify the library of promoter replacement cassettes with a modified start codon and a
10 modified RBS using the mixture of PCR products obtained above as a template. Amplification followed the procedures of example 1. The 1.15 kb PCR products were purified by agarose gel electrophoresis followed by QIAquick gel extraction Kit (QIAGEN).

c) Creation of the library of clones with different artificial promoters with modified start codons and
15 modified RBS in front of the lacZ genes.

Transformants carrying Red Helper plasmid (pKD 46) (Datsenko and Wanner, *supra*) were grown in 20 ml SOB medium with carbenicillin (100 mg/l) and L arabinose (10mM) at 30°C to an OD_{550nm} of 0.6 and then made electrocompetent by concentration 100 fold and washed one time with ice water and twice with ice cold 10% glycerol. Electroporation was done using a Gene pulse
20 (BioRad - model II apparatus 165-2106) with a voltage booster and 0.2 cm chambers according to manufactures instructions by using 50 µl of cells and 0.1 to 1.0 µg of the purified PCR products (as described above). Shocked cells were added to 1 ml SOC medium incubated 2 hours at 30°C and then half of the cells were spread on agar to select Cm^R transformants. Xgal 40 mg/l was added on the agar plates to evaluate the β galactosidase expression. If cells did not grow within 24 hours, the
25 remainder were spread after standing overnight at 30°C.

d) PCR verification of the transformants.

Mutants were grown overnight on LB medium with 30 mg/l Cm. 1.0 ml of culture was washed with ice cold water and the chromosomic DNA was recovered in the supernatant after heat
30 treatment (5 min at 94°C) of the washed cells.

The PCR was performed using the chromosomic DNA and a set of two oligonucleotides, LacseqF and LacseqR as disclosed above in example 1. Amplification also followed the protocol of example 1. A 1.6kb PCR product was obtained. The PCR product was digested by ECORV (1U/µg of ECORV, 2 hrs at 37C). The comparison of the digestion profile of the mutants with the wild-type
35 strain showed that the ECORV site disappeared with the promoter replacement.

The sequence of the GI promoter in the different clones was determined by sequencing the different PCR products with the lacseqF primer. 50 µl of column-purified PCR products (QIAquick, Qiagen, Inc.) obtained from the chromosomic DNA of the mutants were used and sequenced by

- 30 -

Genome Express (Meylan, France). The organization of the upstream region of lacZ in four of the recombinant clones obtained was as expected.

1.6GI - clone 1: start codon - TTG; RBS - TCACAGGAGA; β -galactosidase activity, 0.28U/mg;

1.6GI - clone 2: start codon - ATG; RBS - AAGGAGGAA; β -galactosidase activity, 5.7U/mg;

5 1.2GI - clone 3: start codon - ATG; RBS - ACACAGGAAA; β -galactosidase activity, 0.68U/mg; and

1.6GI - clone 4: start codon - TTG; RBS - ACACAGAAGA; β -galactosidase activity, 0.032U/mg.

Those skilled in the art will recognize or be able to ascertain using not more than routine experimentation, many equivalents to the specific embodiments of the invention described herein.

10 Such equivalents are intended to be encompassed by the following claims.

CLAIMS

1. A method of creating a library of artificial promoters comprising
 - a) obtaining an insertion DNA cassette, which comprises, a first recombinase site, a second recombinase site and a selective marker gene located between the first and the second recombinase sites;
 - b) obtaining a first oligonucleotide which comprises, i) a first nucleic acid fragment homologous to an upstream region of a chromosomal gene of interest, and ii) a second nucleic acid fragment homologous to a 5' end of the insertion DNA cassette;
 - c) obtaining a second oligonucleotide which comprises, i) a third nucleic acid fragment homologous to a 3' end of said insertion DNA cassette, ii) a precursor promoter comprising a -35 consensus region (-35 to -30), a linker sequence and a -10 consensus region (-12 to -7), wherein the linker sequence comprises between 14 - 20 nucleotides and is flanked by the -35 region and the -10 region, wherein said precursor promoter has been modified to include at least one modified nucleotide position of the precursor promoter and wherein the -35 region and the -10 region each include between 4 to 6 conserved nucleotides of the promoter, and iii) a fourth nucleic acid fragment homologous to a downstream region of the transcription start site of the promoter; and
 - d) mixing the first oligonucleotide and the second oligonucleotide in an amplification reaction with the insertion DNA cassette to obtain a library of double stranded amplified products comprising artificial promoters.
2. The method according to claim 1 further comprising purifying the amplified products.
3. The method according to claim 1, wherein the amplification step is a polymerase chain reaction step.
4. The method according to claim 1, wherein the -35 region of the precursor promoter is selected from the group consisting of TTGACA, TTGCTA, TTGCTT, TTGATA, TTGACT, TTTACA and TTCAAA.
5. The method according to claim 1, wherein the -35 region of the precursor promoter comprises a modification to the -30 residue of the precursor promoter.
6. The method according to claim 1, wherein the -10 region of the precursor promoter is selected from the group consisting of TAAGAT, TATAAT, AATAAT, TATACT, GATACT, TACGAT, TATGTT and GACAAT.

- 32 -

7. The method according to claim 1, wherein the -35 region of the precursor promoter is TTGACA and the -10 region of the precursor promoter is TATAAT.

8. The method according to claim 1, wherein the 35 region of the precursor promoter is TTGACA and the -10 region of the precursor is AATAAT.

9. The method according to claim 1, wherein the linker sequence comprises between 16 and 18 nucleotides.

10. The method according to claim 1, wherein the precursor promoter is obtained from a promoter selected from the group consisting of P_{trc} (SEQ ID NO 2); P_{D/E20} ((SEQ ID NO. 4); P_{H207} (SEQ ID NO. 3); P_{N25} (SEQ ID NO. 5); P_{G25} (SEQ ID NO.6); P_{J5} (SEQ ID NO.7); P_{A1} (SEQ ID NO. 8); P_{A2} (SEQ ID NO. 9); P_{A3} (SEQ ID NO. 10); P_{lac} (SEQ ID NO. 1); P_{Gl} (SEQ ID NO. 15); P_{lacUV5} (SEQ ID NO. 12); P_{CON} (SEQ ID NO.4); and P_{bis} (SEQ ID NO. 14).

11. The method according to claim 1, wherein the library of artificial promoters includes SEQ ID NO. 15, SEQ ID NO. 16 and SEQ ID NO. 17.

12. The method according to claim 1, wherein the precursor promoter and the chromosomal gene of interest are heterologous.

13. The method according to claim 1, wherein the precursor promoter and the chromosomal gene of interest are homologous.

14. The method according to claim 1 further comprising modifying the ribosome binding site including,

- d) obtaining a third oligonucleotide which comprises,
 - i) a fifth nucleic acid fragment homologous to the 5' end of said chromosomal gene of interest,
 - ii) a modified ribosome binding site of the gene of interest, said ribosome binding site includes at least one modified nucleotide, and
 - iii) a sixth nucleic acid fragment homologous to a downstream region of the -10 region of the second oligonucleotide; and
- e) mixing the PCR products of claim 1 with the third oligonucleotide and the first oligonucleotide of claim 1 in a PCR reaction to obtain PCR products comprising artificial promoters with modified ribosome binding sites.

15. The method according to claim 14, wherein the ribosome binding site from the precursor promoter is selected from the group consisting of AGGAAA, (SEQ ID NO. 30), AGAAAA

- 33 -

(SEQ ID NO. 31), AGAAGA (SEQ ID NO. 32), AGGAGA (SEQ ID NO. 33), AAGAAGGAAA (SEQ ID NO. 34), AAGGAAAA (SEQ ID NO. 35), AAGGAAAG (SEQ ID NO. 36), AAGGAAAU (SEQ ID NO. 37), AAGGAAAA (SEQ ID NO. 38), AAGGAAAAG (SEQ ID NO. 39), AAGGAAAAU (SEQ ID NO. 40), AAGGAAAAAA (SEQ ID NO. 41), AAGGAAAAAG (SEQ ID NO. 42), AAGGAAAAAU (SEQ ID NO. 43), AAGGAAAAAAA (SEQ ID NO. 44), AAGGAAAAAAG (SEQ ID NO. 45), AAGGAAAAAAU (SEQ ID NO. 46), AAGGAAAAAAA (SEQ ID NO. 47), AAGGAAAAAAG (SEQ ID NO. 48), AAGGAAAAAAAU (SEQ ID NO. 49), AAGGAAAAAAA (SEQ ID NO. 50), AAGGAAAAAAG (SEQ ID NO. 51), AAGGAAAAAAAU (SEQ ID NO. 52), AAGGAAAAAAA (SEQ ID NO. 53), AAGGAAAAAAG (SEQ ID NO. 54), AAGGAGGAAA (SEQ ID NO. 55), and AAGGAAAAAAAU (SEQ ID NO. 56).

16. The method according to claim 14 further comprising inserting a stabilizing mRNA sequence between the modified ribosome binding site and a transcription initiation site of the third oligonucleotide.

17. The method of claim 14, further comprising altering the start codon of the gene of interest in the third oligonucleotide.

18. The method according to claim 1 further comprising,
d) obtaining a third oligonucleotide comprising
i) a fifth nucleic acid fragment homologous to the 5' end of the chromosomal gene of interest in claim 1,
ii) a start codon of the gene of interest, wherein said start codon is degenerated and includes at least one modification oligonucleotide and
iii) a sixth nucleic acid fragment homologous to the downstream region of the -10 region of the second oligonucleotide, and
e) mixing the PCR products of claim 1 with the third oligonucleotide and the first oligonucleotide in a PCR reaction to obtain PCR products comprising artificial promoters with modified start codons.

19. The method according to claim 17 further comprising inserting a stabilizing mRNA sequence between the -10 box of the artificial promoter and a transcription initiation site of the third oligonucleotide.

20. The artificial promoter library produced by the method of claim 1.

21. The artificial promoter library produced by the method of claim 2.

- 34 -

22. An artificial promoter library comprising a mixture of double stranded polynucleotides which include in sequential order:
- a) a nucleic acid fragment homologous to an upstream region of a chromosomal gene of interest,
 - b) a first recombinase site,
 - c) a nucleic acid sequence encoding an antimicrobial resistance gene,
 - d) a second recombinase site,
 - e) two consensus regions of a promoter and a linker sequence, wherein the first consensus region comprises a -35 region, the second consensus region comprises a -10 region and the linker sequence comprises at least 14 - 20 nucleotides and is flanked by the first consensus region and wherein the -35 region and the -10 region each include between 4 - 6 conserved nucleotides of corresponding consensus regions of the promoter, and
 - f) a nucleic acid fragment homologous to the downstream region of the +1 transcription start site of the promoter.
23. The artificial promoter library of claim 22, wherein the double stranded polynucleotides further include a modified ribosome binding site of the promoter wherein said binding site is located between the -10 region and the nucleic acid sequence homologous to the downstream region of the +1 transcription start site.
24. The artificial promoter library of claim 22, wherein the double stranded polynucleotides further include a modified start codon, wherein the modified start codon sequence is located between the -10 region and the nucleic acid sequence homologous to the downstream region of the +1 transcription start site.
25. The artificial promoter library of claim 22, wherein the double stranded polynucleotides further include a stabilizing mRNA nucleic acid sequence, wherein the stabilizing mRNA sequence is located between the -10 region and the nucleic acid sequence homologous to the downstream region of the +1 transcription start site.
26. The artificial promoter library of claim 22, wherein the -35 region includes a substitution in one nucleotide position with the remaining nucleotide positions conserved.
27. The artificial promoter library of claim 26, further including a substitution in one nucleotide position of the -10 region with the remaining nucleotide positions conserved.
28. A method of modifying a promoter in selected host cells comprising

- a) obtaining a library of PCR products comprising artificial promoters according to claim 1;
 - b) transforming bacterial host cells with the PCR library, wherein the PCR products comprising the artificial promoters are integrated into the bacterial host cells by homologous recombination;
 - c) growing the transformed bacteria cells;
 - d) selecting the transformed bacterial cells comprising the artificial promoters.
29. A method of modifying a promoter in selected host cells comprising
- a) obtaining a library of PCR products comprising artificial promoters according to claim 14;
 - b) transforming bacterial host cells with the PCR library, wherein the PCR products comprising the artificial promoters are integrated into the bacterial host cells by homologous recombination to produce transformed bacterial cells;
 - c) growing the transformed bacteria cells;
 - d) selecting the transformed bacterial cells comprising at least one artificial promoter.
30. A method of modifying a promoter in selected host cells comprising
- a) obtaining a library of PCR products comprising artificial promoters according to claim 18;
 - b) transforming bacterial host cells with the PCR library, wherein the PCR products comprising the artificial promoters are integrated into the bacterial host cells by homologous recombination to produce transformed bacterial cells;
 - c) growing the transformed bacteria cells;
 - d) selecting the transformed bacterial cells comprising at least one artificial promoter.
31. The method according to claim 28, wherein the bacterial host cell is selected from the group consisting of *E. coli*, *Pantoea sp.* and *Bacillus sp.*
32. The method according to claim 29, wherein the bacterial host cell is selected from the group consisting of *E. coli*, *Pantoea sp.* and *Bacillus sp.*
33. The method according to claim 30, wherein the bacterial host is selected from the group consisting of *E. coli*, *Pantoea sp.* and *Bacillus sp.*
34. A method of creating a library of bacterial cells having a range of expression levels of a chromosomal gene of interest comprising,

- 36 -

a) obtaining a library of PCR products comprising artificial promoters according to claim 1;

b) transforming bacterial host cells with the PCR products, wherein the PCR products comprising the artificial promoters are integrated into bacterial host cells by homologous recombination to produce transformed bacterial cells;

c) growing the transformed bacteria cells; and

d) obtaining a library of transformed bacterial cells wherein the library exhibits a range of expression levels of a chromosomal gene of interest.

35. The method according to claim 34, further comprising selecting transformed bacterial cells from the library.



36. The method of claim 35, wherein the selected transformed bacterial cells have a low level of expression of the gene of interest.

37. The method of claim 35, wherein the selected transformed bacterial cells have a high level of expression of the gene of interest.

38. The method according to claim 35 further comprising excising the selective marker gene from the transformed bacterial cells.

39. Transformed bacterial cells selected according to the method of claim 35.

40. The method according to claim 35, wherein the bacterial host cell is an *E. coli*, *Bacillus sp.* or *Pantoea sp.* cell.






FIG..2

FIGURE 3





FIGURE 4

	-50	-7	+1	+20	
PH/E20	AACTGCAAAAATAGT TTGACA CCTAGCCGATAGGCTT TAAGAT GTACCCAGTTCGATGAGAGCGATAAC				(SEQ ID NO. 3)
PH207	TTTTAAAAAATTCTAT TTGCTA AACGCTTCAAATTCCTG TATAAT ATACTTCATAAATTGATAAACAAAA				(SEQ ID NO. 4)
PN25	TCATAAAAAAATTTAT TTGCTT TCAGGAAAATTTTTCTG TATAAT AGATTCTATAAATTGAGAGAGGAGTT				(SEQ ID NO. 5)
PG25	TGAAAAATAAAAATTC TTGATA AAATTTTCCAATACTAT TATAAT ATTGTTATTAAAGAGGAGAAAAATTAAAC				(SEQ ID NO. 6)
PJ5	ATATAAAAAACCGTTA TTGACA CAGGTGGAAATTTAGAA TATACT GTTAGTAAACCTAATGGATCGACCTT				(SEQ ID NO. 7)
PA1	TTATCAAAAAAGAGTA TTGACT TAAAGTCTAACCCTATAG GATACT TACAGCCATCGAGAGGGACACGGCGA				(SEQ ID NO. 8)
PA2	CACGAAAAACAGGTA TTGACA ACATGAAGTAACATGCAGTAAAGAT ACAAATCGCTAGGTAACACTAGACGC				(SEQ ID NO. 9)
PA3	GGTGAACAACAAACGG TTGACA CACTGAAGTAACACACGG TACGAT GTACCACATGAAACGACAGTGAGTCA				(SEQ ID NO. 10)
PL	TTATCTCTGGCGGTG TTGACA TAAATACCACCTGGCGGT GATACT GAGCACATCAGCAGGACGCACCTGACC				(SEQ ID NO. 11)
Plac	TTAGGCACCCACGGC TTTACA CTTTATGCTTCCGGCTGGTATGTT GTGTGGAAATTGTGAGCGATAACAAT				(SEQ ID NO. 1)
PlacUV5	CTAGGCACCCACGGC TTTACA CTTTATGCTTCCGGCTGGGTATAAT GTGTGGAAATTGTGAGCGGATAACAAT				(SEQ ID NO. 12)
Ptaci	TTCTGAAATGAGCTG TTGACA ATTAATCATCGGCTCG TATAAT GTGTGGAAATTGTGAGCGGATAACAAT				(SEQ ID NO. 2)
Pcon	AAITCACCGTCGTTG TTGACA TTTTAAAGCTTGGCGGT TATAAT GGTACCATAAGGAGGTGGATCCGGCA				(SEQ ID NO. 13)
Pb1s	TTTTTTCTAAATACA TTCAAA TATGTATCCGCTCATGA GACAAT AACCCCTGATAAATGCTTCAATAATAT				(SEQ ID NO. 14)



Chromosomal Organization of the Lactose Operon of the Wild Type Strain of *E. coli*

Chromosome Organization of the Lactose Operon of the Recombinant Strain of *E. coli* on Chloramphenicol

FIG. 5

FIGURE 6

pLAC (SEQ ID NO. 18)
 AGGC TTTACA CTTATGCTTCGGGCTCG TATGTT GTGTGGA ATTGTGAGCGGATAACAATTTTCACACAGGAAACAGCT ATGACC
 -35 RBS Start

1.6Gl lacZ (SEQ ID NO. 19)
 GCCC TTGACA ATGCCACATCCTGAGCA AATAAT TCAACCACT AATTGTGAGCGGATAACAATTTTCACACAGGAAACAGCT ATGACC
 -35 -10 RBS start

GI 1.6 (SEQ ID NO. 15)
 GCCC TTGACA ATGCCACATCCTGAGCA AATAAT TCAACCACTAATTGTGAGCGGATAACA



1.5Gl lacZ (SEQ ID NO. 20)
 GCCC TTGACT ATGCCACATCCTGAGCA AATAAT TCAACCACT AATTGTGAGCGGATAACAATTTTCACACAGGAAACAGCT ATGACC
 -35 -10 RBS start

GI 1.5 (SEQ ID NO. 16)
 GCCC TTGACT ATGCCACATCCTGAGCA AATAAT TCAACCACTAATTGTGAGCGGATAACA

1.20Gl lacZ (SEQ ID NO. 21)
 GCCC TTGACG ATGCCACATCCTGAGCA AATAAT TCAACCACT AATTGTGAGCGGATAACAATTTTCACACAGGAAACAGCT ATGACC
 -35 -10 RBS start

GI 1.2 (SEQ ID NO. 17)
 GCCC TTGACG ATGCCACATCCTGAGCA AATAAT TCAACCACTAATTGTGAGCGGATAACA

7 / 7



Transformants	Stabilizing Sequence	RBS Sequence	Specific Activity (U/mg)
mLac RNA 1	GGTCGAG	AAGGAGGAAA	5.71
mLac RNA 2	GGTGGAG	AAGGAGGAAA	11.04
mLac RNA 3	CCTCGAG	AAGGAGGAAA	18.44
mLac RNA 4	GGTGGAC	AAGGAGGAAA	7.3
mLac RNA 5	GCTGGAC	AAGGAGGAAA	4.11
Wild-type Strain +IPTG	NO	AGGAAA	1.21

FIG. 9

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number
WO 2003/089605 A3

(51) International Patent Classification⁷: C12Q 1/68,
C12P 19/34, C07H 21/02

(21) International Application Number:
PCT/US2003/012045

(22) International Filing Date: 18 April 2003 (18.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/374,627 22 April 2002 (22.04.2002) US

(71) Applicant (for all designated States except US): GENENCOR INTERNATIONAL, INC. [US/US]; 925 Page Mill Road, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SOUCAILLE, Philippe [FR/FR]; Chant du Coucou, F-31450 Deyme (FR). CERVIN, Marguerite, A. [CA/US]; 404 Palomar Dr., Redwood City, CA 94062 (US). VALLE, Fernando [US/US]; 232 Bancroft Road, Burlingame, California 94010 (US).

(74) Agent: ITO, Richard, T.; GENENCOR INTERNATIONAL, INC., 925 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the International search report:
2 December 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF CREATING A LIBRARY OF BACTERIAL CLONES WITH VARYING LEVELS OF GENE EXPRESSION

(57) Abstract: The present invention relates to a method of creating DNA libraries that include an artificial promoter library and/or a modified ribosome binding site library and transforming bacterial host cells with the library to obtain a population of bacterial clones having a range of expression levels for a chromosomal gene of interest.

WO 2003/089605 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/12045

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/68; C12P 19/34; C07H 21/02

US CL : 435/6, 91.2; 536/23.1, 24.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.2; 536/23.1, 24.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	WO 94/25609 A1 (HYBRITECH INCORPORATED) 10 November 1994 (10.11.1994), see entire document.	1-3 4-19
X — Y	WO 98/07846 A1 (JENSEN et al) 26 February 1998 (26.02.1998), see entire document.	1-9, 12-19 10-11

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

14 September 2004 (14.09.2004)

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Date of mailing of the international search report

18 OCT 2004

Authorized officer

Jeffrey Fredman

Telephone No. 571-272-1600

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/12045

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-19, SEQ ID NO: 1

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US03/12045

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Groups 1-42, claim(s) 1-19, drawn to methods of creating libraries of artificial promoters, where each Group corresponds to a different SEQ ID NO, with Group 1 being SEQ ID NO: 1 of claim 10, Group 2 being SEQ ID NO: of claim 10 ... Group 13 being SEQ ID NO: 15 of claim 10, Group 14 being SEQ ID NO: 30 of claim 15, etc.

Group 43, claim(s) 20-27, drawn to artificial promoter libraries.

Group 44, claim(s) 28-38, 40, drawn to methods of modifying promoters.

Group 45, claim(s) 39, transformed bacterial cells.

The inventions listed as Groups 1-45 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The products claimed in Group 43, Claims 20-27 are drawn to artificial promoter libraries. However, such libraries are taught by Jensen et al (WO 98/07846) who teaches artificial promoter libraries (see abstract). Accordingly, the claims are sufficiently broad so as to encompass artificial promoter libraries taught in the art. As the products of Groups 20-27 do not represent a contribution over the prior art, the claims lack a special technical feature that is the same as or that corresponds to a special technical feature of the other claimed inventions. Thus, there is no special technical feature linking the recited Groups, as would be necessary to fulfill the requirement for unity of invention.

It is also noted that each of the present claims has been presented in improper Markush format, as distinct products and distinct methods are improperly joined in the claims. With respect to claims 1-19, each nucleic acid sequence of specific SEQ ID NO: is structurally and functionally distinct from and has a different special technical feature than each other nucleic acid sequence. The chemical structure of each nucleic acid molecule differ from each other. For example, a polynucleotide comprising SEQ ID NO: 1 is chemically, structurally, and functionally different from a molecule comprising SEQ ID NO: 2. As the products and methods encompassed by the claims do not share a special technical feature, the distinct products and methods may not properly be presented in the alternative. Accordingly, the claims have been separated into a number of groups corresponding to the number of different inventions encompassed by the claims, and the claims will be examined only as they read upon the invention of the elected group. For the same reasons, the remainder of the claims have been separated in a number of groups corresponding to the number of different inventions encompassed thereby.

Continuation of B. FIELDS SEARCHED Item 3:

EAST, MEDLINE, BIOSIS, CAPLUS

search terms: library, promoter, artificial, DNA, nucleic, oligonucleotide, polynucleotide, RNA, -35 consensus, -10 consensus, enhancer, PCR, polymerase, chain.